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ABSTRACT 
 
The number of people suffering from type 2 diabetes (T2D) and related diseases is 
expected to rise to epidemic levels by the year 2030. Estimates indicate that 366 million 
individuals worldwide and more than 500 000 in Finland - roughly 10-16% of adult 
men and 7-11% of women - have T2D. Furthermore, an undefined, yet vast, number of 
individuals are at increased risk for T2D and pre-diabetes. Insulin resistance (IR) and 
deficiency in insulin secretion are the two main features of T2D. This thesis focuses on 
these two components. In addition, this thesis focuses on the metabolic syndrome 
(MetS) which refers to a cluster of aberrations of metabolic origin that increases one’s 
risk for T2D. Along with the estimated world-wide increase in the prevalence of T2D, 
there exists a strong need to identify factors that may render an individual susceptible to 
the disease. T2D is multifactorial in origin and is thought to arise from a combination of 
genetic and environmental factors. This thesis focuses on depression, poor sleep quality 
and stressful life events as plausible environmental factors that may increase one’s risk 
for T2D. The thesis aims to contribute to the surprisingly scanty and elusive literature 
on the role of these environmental psychosocial risk factors by testing (a) their 
associations with IR, insulin secretion and/or the MetS; and (b) whether antidepressant 
medication contributes to associations of depressive symptoms with IR and the MetS; 
and c) whether these associations depict individuals without manifest or latent T2D. 
These study questions were addressed in the Prevalence, Prediction and Prevention of 
Diabetes, the PPP-Botnia Study, comprising 5208 participants (2443 men and 2765 
women). These study participants underwent a detailed clinical examination, including 
an oral glucose tolerance test in conjunction with which, they self-reported their 
depressive symptoms, sleep quality and exposure to stressful life events. 
The results showed that depressive symptoms (Study I); poor sleep quality, as 
reflected in subjective sleep complaints of sleep apnea, insomnia and daytime sleepiness 
(Study II); and stressful life events – particularly events related to finance and work – 
and  the  accumulation  of  stressful  life  events  in  any  domain  of  stress  (Study  IV)  were  
associated with a higher likelihood of IR. In addition, depressive symptoms and 
stressful life events were associated with the MetS (Studies III & IV). No evidence was 
found to support the association of psychosocial factors with deficient insulin secretion 
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(Studies  I,  II  & IV)  or  that  the  use  of  antidepressant  medication  drove  associations  of  
depressive symptoms with IR and the MetS (Studies I & III). These associations 
depicted men and women without manifest or latent T2D (Studies I-IV) as well as men 
and women whose glucose tolerance was within a normoglycemic range (Study II). The 
findings of this thesis thus suggest that depressive symptoms, poor sleep quality and 
stressful life events are associated with a higher likelihood of IR and having the MetS, 
but are not associated with indices of deficient insulin secretion. In addition, these 
associations characterise individuals without manifest or latent T2D. Overall, the 
findings, though cross-sectional, seem to suggest that psychosocial factors increase 
one’s  risk  for  T2D by  way of  increasing  one’s  risk  for  IR.  The  findings  of  this  thesis  
implicate that strategies aiming to reduce depression, improve poor sleep quality and 
alleviate stress in individuals without T2D may offer an additional tool in diabetes 
prevention.  
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TIIVISTELMÄ 
 
Tyypin 2 diabetes (T2D) ja sen aiheuttamat liitännäissairaudet ovat maailmanlaajuisten 
ennusteiden mukaan kasvamassa epidemiaksi vuoteen 2030 mennessä. On arvioitu, että 
366 miljoonaa ihmistä maailmanlaajuisesti ja yli 500 000 ihmistä Suomessa, eli noin 
10–16% aikuisista miehistä ja 7–11 % naisista, sairastaa T2D:tä. Tämän lisäksi 
tarkemmin määrittelemätön, mutta suuri määrä ihmisiä on kohonneessa vaarassa 
sairastua diabetekseen. Insuliiniresistenssi (IR) ja heikentynyt insuliinin tuotanto ovat 
T2D:n pääpiirteitä. Tämä väitöstutkimus keskittyy tutkimaan näitä kahta pääpiirrettä. 
Lisäksi tutkimuksessa tarkastellaan metabolista oireyhtymää (MetS), joka koostuu 
aineenvaihdunnallisista poikkeamista ja diabeteksen vaaratekijöistä, jotka lisäävät 
vaaraa sairastua T2D:een. Koska maailmanlaajuisesti T2D:tä sairastavien määrä on 
kasvussa, tarve tunnistaa sairaudelle altistavia tekijöitä on suuri. T2D taustalla 
vaikuttavat niin geneettiset kuin ympäristöön liittyvät tekijät. Tämä väitöstutkimus 
tarkastelee depressiota, huonoa unenlaatua ja stressaavia elämäntapahtumia 
ympäristötekijöinä, jotka saattavat lisätä vaaraa sairastua T2D:seen. Tämän 
väitöstutkimuksen tarkoituksena on tuottaa lisää tutkimustietoa näiden tekijöiden 
merkityksestä nykyisen, ja yllättävän niukan, tiedon oheen seuraavilla tavoilla: a) 
tutkimuksessa tarkastellaan depression oireiden, huonon unen laadun ja stressaavien 
elämäntapahtumien yhteyttä IR:ään, insuliinin tuotantoon ja/tai MetS:siin, b) 
tarkastellaan, ovatko depressio-oireiden mahdolliset yhteydet IR:ään ja MetS:iin 
seurausta mielialalääkkeiden käytöstä sekä c) tutkitaan kaikkia edellä mainittuja 
yhteyksiä henkilöillä, joilla ei ole todettua tai piilevää T2D:tä. Näihin 
tutkimuskysymyksiin haettiin vastauksia Prevalence, Prediction and Prevention of 
diabetes (Diabeteksen Esiintyvyys, Ennustettavuus ja Ennaltaehkäisy), PPP-Botnia –
tutkimuksen avulla. Tutkittavien joukko koostui 5208 henkilöstä (2443 miestä ja 2765 
naista). Tutkittavat osallistuivat sokerirasitustestiin, jossa nautittiin suun kautta 
glukoosia. Tämän tutkimuksen yhteydessä tutkittavat raportoivat depressio-oireistaan, 
unenlaadustaan sekä heitä kohdanneista stressaavista elämäntapahtumista. 
Tulokset osoittivat, että depressio-oireet (Tutkimus I), huono unen laatu, joka ilmeni 
subjektiivisina useammin toistuvina uniapnean, päiväaikaisen väsymyksen ja 
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unettomuuden oireina (Tutkimus II), ja stressaavat elämäntapahtumat, jotka liittyivät 
erityisesti taloudellisiin huoliin ja työelämään sekä stressaavien elämäntapahtumien 
kasautuminen kaikilla elämän osa-alueilla (Tutkimus IV), olivat yhteydessä suurempaan 
todennäköisyyteen kärsiä insuliiniresistenssistä. Depressio-oireet ja stressaavat 
elämäntapahtumat olivat myös yhteydessä MetS:iin (Tutkimukset III & IV). Näiden 
psykososiaalisten tekijöiden yhteyttä heikentyneeseen insuliinin tuotantoon ei havaittu 
yhdessäkään tutkimuksessa (Tutkimukset I, II & IV). Tämän lisäksi havaittiin, etteivät 
depressio-oireiden ja IR:n ja MetS:in yhteydet selity mielialalääkkeiden käytöllä 
(Tutkimukset I & III). Lisäksi yhteydet olivat tilastollisesti merkitseviä niillä miehillä ja 
naisilla, jotka eivät sairasta todettua tai piilevää T2D:tä, ja joiden verensokeriarvot 
olivat normaalien rajojen sisällä (Tutkimus II). Tämän tutkimuksen tulokset osoittavat, 
että depressio-oireet, huono unenlaatu ja stressaavat elämäntapahtumat ovat yhteydessä 
suurempaan todennäköisyyteen kärsiä insuliiniresistenssistä ja MetS:stä, mutta eivät ole 
yhteydessä insuliinin tuotannon heikentymiseen. Vaikka tulokset perustuvat 
tutkimusasetelmaan poikkileikkausaineistossa, tulokset kokonaisuudessaan viittaavat 
siihen, että psykososiaaliset tekijät lisäävät T2D:n riskiä lisäämällä insuliiniresistenssin 
riskiä. Tämän väitöstutkimuksen johtopäätöksenä voidaan todeta, että toimenpiteet, 
jotka tähtäävät depressio-oireiden vähentämiseen, unenlaadun parantamiseen sekä 
stressin lievittämiseen, voivat toimia yhtenä uutena keinona diabeteksen ehkäisyssä. 
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1 INTRODUCTION 
 
It has been forecasted that by the year 2030 diabetes will be among the top five causes 
of death in the world and will account for nearly 5% of deaths and of the disease burden 
in industrialized high-income countries (Mathers & Loncar, 2006). According to 
another forecast the number of people with diabetes will double from 171 million in 
year 2000 to 366 million in year 2030 (Wild, Roglic, Green, Sicree, & King, 2004). 
However, the actual number of people with diabetes might even be greater. According 
to the International Diabetes Foundation (IDF) already in 2011 366 million people had 
diabetes, and the IDF predicted that some 522 million people will have diabetes by the 
year 2030 (International Diabetes Foundation, 2011). These numbers suggest that the 
increase in the prevalence of diabetes might even be accelerating. Consequently, a 
Finnish study found, that diabetes contributes to 8% of deaths in Finnish men and 11% 
in women (Manderbacka, Peltonen, Koskinen, & Martikainen, 2011). Worldwide, the 
IDF estimates that 4.6 million deaths were due to diabetes in 2011 (International 
Diabetes Foundation, 2011). In the face of the diabetes epidemic, research on causative 
factors behind the increase in incidence of diabetes, and preventative measures, are 
urgently needed. 
 
1.1 Type 2 diabetes, insulin resistance, deficiency in insulin 
secretion and the metabolic syndrome 
 
Type 2 Diabetes (T2D) is a heterogeneous syndrome characterized by abnormalities in 
carbohydrate and fat metabolism. It is multifactorial in origin – genetic and 
environmental factors are likely to contribute. Central features of T2D include insulin 
resistance (IR) and progressive pancreatic ?-cell deterioration resulting in impaired 
insulin secretion and release, and increased hepatic glucose production as the result of 
enhanced glycogenolysis and gluconeogenesis (Alberti & Zimmet, 1998; Taylor, 2008; 
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003). 
IR is a physiological condition where the hormone insulin, is not showing the expected 
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magnitude of effects on target cells at lowering glucose levels (S.E. Kahn, 2003). IR, 
especially in people with obesity or T2D, is manifested by decreased insulin-stimulated 
glucose transport and metabolism in adipocytes and skeletal muscle, and by impaired 
suppression of hepatic glucose output (Codario, 2011; G. Reaven, 2002; Taylor, 2008). 
Regulation of postprandial glucose depends upon stimulation of insulin secretion 
with subsequent suppression of hepatic gluconeogenesis and glycogenolysis (Taylor, 
2008). Insulin release subsequently promotes glucose uptake in the muscle and the 
peripheral tissues. The earliest manifestation of the T2D is elevation of postprandial 
glucose in association with progressive IR. This results in compensatory pancreatic islet 
?-cell hypertrophy, but eventually insulin production is insufficient to maintain 
euglycemia (Taylor, 2008). Consequently, fasting hepatic glucose production is 
increased in both obese and non-obese diabetics compared to normal individuals and 
those with impaired glucose tolerance that have not met the criteria for diabetes 
(Codario, 2011; S.E. Kahn, 2003; Taylor, 2008). It is this increase in hepatic glucose 
output due to increases in glyogenolysis and gluconeogenesis that result in fasting 
hyperglycaemia in T2D (Codario, 2011). At some point, usually about 10 years after IR 
and hyperinsulinaemia develop, postprandial hyperglycaemia begins to develop due to 
?-cell dysfunction and or depletion (Codario, 2011). The progressive nature of the 
disease and the progressive lack of glycemic control are due predominately to this 
ongoing deterioration of ?-cell function with subsequent decrease production of insulin 
(Musselman et al., 2003; Taylor, 2008). Although both IR and impaired insulin 
secretion precede the development of postprandial hyperglycaemia and the subsequent 
T2D phenotype, IR is more prominent in the pre-diabetic state and plays an important 
role in the pathogenesis of macrovascular disease (Codario, 2011). 
A number of factors have been suggested as possibly linking IR and ?-cell 
dysfunction in the pathogenesis of T2D. IR can be increased by genetic factors, elevated 
free fatty acids, hyperglycaemia, pregnancy, sedentary life style, aging, and various 
medications (i.e., steroids, estrogens, nicotinic acid, oral contraceptives, phenothiazines, 
and antipsychotic agents) and is characterised by impaired responses on glucose, lipid, 
and protein metabolism (Codario, 2011; Musselman et al., 2003; S.E. Kahn, 2003; 
Taylor, 2008). In addition, a vast majority of individuals suffering from T2D or IR are 
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obese with central visceral adiposity (Björntorp et al., 1991; Björntorp et al., 1993; 
Björntorp et al., 1999; Musselman et al., 2003). Therefore it is likely that the adipose 
tissue plays a crucial, but not definitive, role in the pathogenesis of T2D. In brief, during 
the chronic intake of more energy than is expended each day, fat will accumulate in the 
liver (Taylor, 2008). As this process is promoted by insulin, individuals with a degree of 
IR (determined by family or lifestyle factors) will accumulate liver fat more readily than 
others (Taylor, 2008). As the liver fat increases, the process of glucose production by 
the liver becomes less sensitive to suppression by insulin, plasma glucose tends to rise 
and basal insulin secretion rates rise (S. E. Kahn, 2003). The increased liver fat will 
increase secretion of triglycerides from the liver (Taylor, 2008). All tissues will be 
exposed to more triglycerides than required, but the pancreatic islets are susceptible to 
local triglyceride accumulation (Taylor, 2008). Furthermore, adipose tissue secretes a 
large number of hormones and cytokines, such as interleukin (IL)-1 and IL-6 and   TNF-
? (Hotamisligil, Shargill, & Spiegelman, 1993; Yudkin, Kumari, Humphries, & 
Mohamed-Ali,  2000),  and  these  cytokines  are  considered  to  be  a  key  factor  in  the  
development of IR (Hajer, van Haeften, & Visseren, 2008; Taylor, 2008). 
According to the World Health Organization (WHO) (Alberti & Zimmet, 1998) and 
the American Diabetes Association (ADA) criteria (The Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus, 2003), T2D can be diagnosed by 
fasting glucose level and/or by 2 hour plasma glucose level during an oral glucose 
tolerance test (OGTT) (Table 1). Currently, also a high level of glyceted haemoglobin 
HbA1C (? 6.5%)  has  been  identified  as  an  additional  clinical  criteria  for  T2D  (World  
Health Organization, 2011). However, progress toward T2D can be seen years before 
the onset of manifest disease. A backward extrapolation of findings made in the United 
Kingdom Prospective Diabetes Study cohort from shortly after the clinical diagnosis of 
T2D  strongly  suggests  that  ?-cell  dysfunction  commences  years,  at  least  10  years,  
before hyperglycaemia develops (U.K. prospective diabetes study group, 1995). At first, 
dysfuntion in glucose metabolism and insulin secretion can be seen in people with 
impaired fasting glucose (IFG), reflecting hepatic IR, and with impaired glucose 
tolerance (IGT), reflecting skeletal muscle IR and ?-cell failure (Abdul-Ghani, Tripathy, 
& DeFronzo, 2006). These two impairments are intermediate states between normal 
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glucose homeostasis and overt diabetes, and are thus considered pre-diabetic conditions 
(for definitions and cut-offs please see Table 1).  
 
 
 
The golden standard of measuring IR is the hyperinsulinaemic euglycaemic clamp 
technique. However, less time and money consuming methods (e.g OGTT) have been 
presented  to  better  suit  epidemiological  studies.  Based  on  OGTT  values  several  
surrogate measures of IR and insulin secretion have been presented (Table 2). 
Homeostasis Model Assessment Method (HOMAIR) and Insulin Sensitivity Index (ISI) 
represent surrogate measures of IR/insulin sensitivity and Corrected Insulin Response 
(CIR) and Disposition Index (DI) measures of insulin secretion, i.e. ? cell functionality. 
In addition, Area Under the Curve (AUC) of glucose and insulin represent another 
surrogate measure of IR indicating abnormal glucose and insulin levels over two hour 
period. The estimate of IR obtained by HOMAIR has been found a valid as it has been 
found to correlate with estimates obtained by use of the euglycaemic clamp, the fasting 
insulin concentration, and the hyperglycaemic clamp (Matthews et al., 1985). In 
addition, ISI has also been found a valid method of assessing overall insulin sensitivity 
in  normal  and  insulin  resistant  non-diabetic  subjects  (Bergman,  Prager,  Volund,  &  
Olefsky, 1987). Also a similar and significant relationship has been observed between 
hepatic insulin sensitivity and the HOMAIR regardless of the stage of glucose tolerance 
(Tripathy, Almgren, Tuomi, & Groop, 2004). Furthermore, DI describes the pancreatic 
?-cell sensitivity-secretion relationship as a rectangular hyperbola (Bergman, Ader, 
Huecking, & Van Citters, 2002), and CIR has been found a valid method of assessing 
Table 1. WHO and ADA definitions of T2D, IGT, and IFG according to plasma glucose 
levels during OGTT. 
  Units mmol/L 
T2D  ? 7.0 (f) or ? 11.1 (2h) 
IGT No T2D and ? 7.8 (2h) 
IFG:   
ADA No T2D or IGT and ? 5.6 (f) 
WHO No T2D or IGT and ? 6.1 (f) 
Note. f=fasting sample; 2h=sample obtained 2 hours after the oral glucose load 
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insulin secretion as it has been found to  correlate with insulin secretion as measured by 
an intravenous glucose tolerance test (IVGTT) (Hanson et al., 2000). Although 
generally accepted as valid methods of assessing IR, and having both predictive power 
in  estimating  future  diabetes,  ISI  has,  in  this  respect,  been  found  a  slightly  better  
measure of IR than HOMAIR (Tripathy et al., 2004).  
 
Table 2. Surrogate measures of IR and insulin secretion. 
HOMAIR: 
22.5
[mmol/l] glucose plasma fasting × [mU/l]insulin  plasma Fasting
 
 
ISI: 
???
?
???
?
 [pmol/l]insulin  OGTTmean   × [mmol/l] glucose OGTTmean   ×
 [pmol/l]insulin  plasma fasting  × [mmol/l] glucose plasma fasting
10000
 
CIR: ? ?
? ? ? ?mmol/l 3.89 - min. 30at  [mmol/l] glucose ×min. 30at  [mmol/l] glucose
min. 30at  [pmol/l]insulin  ×100
 
DI: ISI × CIR 
AUC of 
insulin: 
15 × fasting plasma insulin [mU/l]  + 15 × insulin [mU/l]  at  30 min + 45 × 
insulin [mU/l] at 30 min + 45 × insulin [mU/l] at 120 min 
AUC of 
glucose: 
15× fasting plasma glucose [mmol/l] + 15 × glucose [mmol/l] at 30 min + 45 
× glucose [mmol/l] at 30 min + 45 × glucose [mmol/l] at 120 min. 
 
The most prevalent condition associated with IR is obesity. However, the 
development of diabetes is not uniform among obese subjects. When excess adipose 
tissue fat is localized to visceral (abdominal, central) fat depots, the risk is higher than 
with peripheral gluteo-femoral obesity (Bergstrom et al., 1990; Ohlsson, Larsson, 
Svärdsudd, Welin, & Eriksson, 1985). Visceral obesity and IR are also main 
components of another risk factor for T2D, the metabolic syndrome (MetS). 
The MetS is a constellation of interrelated risk factors of metabolic origin that appear 
to directly promote the development of atherosclerotic cardiovascular disease and T2D 
20 
 
(National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III), 2002). The risk factors are composed of dysfunctions in glucose metabolism, 
obesity, dyslipidemia and elevated blood pressure (Alberti & Zimmet, 1998; Alberti, 
Zimmet,  Shaw,  &  IDF  Epidemiology  Task  Force  Consensus  Group,  2005;  Grundy  et  
al., 2005; National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III), 2002). The composition of these components has been under scrutiny and various 
definitions for MetS have been presented over the past ten years (Alberti et al., 2005; 
Alberti et al., 2009; Grundy et al., 2005; National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel III), 2002). However, the rationale of 
MetS as a clinical and epidemiological concept has received critique during past years 
due to ill-defined cut-offs of components and because participants with cardiovascular 
disease (CVD) are not excluded by the definition (R. Kahn et al., 2005; R. Kahn, 2006; 
Simmons  et  al.,  2010).  Recently  though,  the  harmonized  criteria  for  MetS  was  
developed by major organizations in order to grasp cultural differences and to unify the 
criteria (Alberti et al., 2009). Despite the criticism, the value of MetS as a clinical tool 
lies in its predictive value. In case of T2D, a Finnish study found that men with MetS 
had fivefold odds for having manifest disease at follow-up (Laaksonen et al., 2002). 
Multinational meta-analysis is in line with these numbers (E. S. Ford, 2005b). 
 
1.2 Scope of the problem: prevalence of type 2 diabetes 
 
T2D makes up about 85 to 95% of all diabetes in high-income countries and may 
account for an even higher percentage in low- and middle-income countries (World 
Health Organization, 1994). It has been found that in 45-74 year old Finns, roughly 7.4% 
in men and 4.3% in women are diagnosed with T2D, but when undiagnosed cases are 
included, the amount of people suffering from T2D is even higher, 15.9% in men and 
11.2% in women (Peltonen et al., 2006). Another Finnish study found among 45-64 
year old subjects that 10.2% of men and 7.4% of women suffer from T2D of which 44% 
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were previously undiagnosed (Ylihärsilä et al., 2005). Indeed, also a multinational study 
has  found  that  most  cases  remain  undetected,  as  up  to  50%  of  those  with  T2D  are  
unaware  of  their  condition  (Expert  Committee  on  the  Diagnosis  and  Classification  of  
Diabetes Mellitus, 2003). This translates roughly to some 200,000 people in Finland 
(Reunanen, 2006), and as 85 to 95% of all diabetes is due to T2D, up to 174 million 
people worldwide (International Diabetes Foundation, 2011). Total number of people 
with T2D is estimated 366 million worldwide (International Diabetes Foundation, 2011) 
and up to 500,000 in Finland alone (Reunanen, 2006). 
An additional number of people are at increased risk for T2D. According to a Finnish 
study, nearly 9.3% of 45-74 year old men and 4.8% of women have a pre-diabetic 
condition, namely IFG (Peltonen et al., 2006). Furthermore, 14.7% men and 15.9% of 
women suffer from another pre-diabetic condition, IGT (Peltonen et al., 2006). 
Prevalence rates are similar to another Finnish study which found among 45-64 year old 
subjects that 13.5% of men and 5.0% of women have IFG, and 10.5% of men and 9.2% 
of women have IGT (Ylihärsilä et al., 2005). Slightly lower prevalence rates might be 
due to a younger population. Altogether, the number of people at risk for T2D is far 
greater than the official number of people with diagnosis and therefore individuals with 
pre-diabetes are the key target group for prevention and intervention. 
In parallel with the diabetes epidemic, obesity and the MetS are increasing with 
alarming rates: by the year 2030 the number of overweight and obese individuals has 
been estimated to increase worldwide from 937 million and 376 million to 1.35 billion 
and 573 million, respectively (Kelly, Yang, Chen, Reynolds, & He, 2008). However, if 
recent secular trends continue unabated, by 2030 up to 57.8% of the world’s adult 
population, that is 3.3 billion people, could be either overweight or obese (Kelly et al., 
2008). Increase in obesity during the past two decades also reflects to increase in the 
prevalence of MetS. In United States the Third National Health and Nutrition 
Examination Survey (NHANES) 1999-2000 (E. S. Ford, Giles, & Mokdad, 2004) 
reported a prevalence of MetS in men by Adult Treatment Panel III (ATP III) definition 
(National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III), 2002) was 30.6%, and in women 33.2%. In addition, the NHANES 1999–2002 
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reported a prevalence of 39.9% for men and 38.1% for women by the IDF (Alberti et 
al., 2005) criteria (E. S. Ford, 2005a). Increase in MetS has also been observed in a 
Finnish population. An epidemiological study of 45-64 year old participants in Finland 
assessing the increase in MetS during 1992-2002 found that the prevalence of MetS in 
men increased from 48.8 to 52.6% between 1992-2002 based on the ATP III definition, 
and from 51.4 to 55.6% based on the IDF definition; in women the prevalence of the 
MetS increased significantly from 32.2 to 39.1% between 1992-2002 based on the ATP 
III definition, and from 38.0 to 45.3% based on the IDF definition (Hu et al., 2008). 
Although an increase was observed in men, it was not statistically significant. 
Prevalence of MetS in Finnish men and women seems higher than that in the United 
States. This is most likely due to the high prevalence of high blood pressure (BP) in 
Finland (Antikainen et al., 2006). 
Meanwhile, apart from causing individual suffering, diabetes burdens the society and 
economy as well.  Worldwide health care expenditures caused by diabetes are estimated 
to be at least 465 billion U.S. Dollars in 2011 representing 11% of total healthcare 
expenditures in adults (20-79 years) and are projected to rise to 595 billion by 2030 
(International Diabetes Foundation, 2011). In Finland, 1.1% of all recipients of 
disability pension are due to diabetes as principal diagnosis according to Finnish Social 
Insurance Institution and in expenditure on diabetes medicines only; the cost for 
reimbursements in 2010 was roughly 150 million Euros (Social Insurance Institution of 
Finland, 2011). In 1997, total health care expenditures due to diabetes in Finland were 
approximately 1.3 billion Euros, and T2D contributed to roughly 86% of this sum 
(Kangas, 2002). However, due to co-morbidity with other somatic and mental disorders, 
the cost of diabetes and related diseases to society is multiplied (International Diabetes 
Foundation, 2011). Altogether, compensation due to reimbursements, sick leave, and on 
the other hand, decrease in productivity at work, represent, even at present, a huge 
burden to the individual, society and economy. Strategies that aim at prevention and 
early intervention are urgently needed. 
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1.3 Psychosocial risk factors 
 
The idea that psychosocial factors may contribute to T2D is not new. In the classic era, 
Epicurus suggested that the mind could be among or influence healing forces in any 
disease. In the years of the Renaissance, Thomas Sydenham extended the Hippocratic 
concept of disease as a systematic disharmony brought about by disturbing forces, when 
he suggested that an individual's adaptive response to such forces could itself be capable 
of producing pathological changes (Chrousos & Gold, 1992). Eventually, in 1675, 
English physician Thomas Willis concluded that “diabetes appeared in patients with 
sadness, prolonged sorrow, or significant life stresses” (Willis, 1675). However, it was 
not until late 20th century when Swedish endocrinologist Per Björntorp paved the path 
for modern psychosomatic research. In his widely acknowledged biological theory 
Björntorp proposed that psychosocial pressure contributes to hypothalamo-pituitary-
adrenal axis (HPAA) dysfunctions manifesting in fat accumulation and IR (Björntorp, 
1991; Björntorp, 1997; Björntorp et al., 1999). The HPAA is a central control and 
regulatory system of the organism that connects the central nervous system with the 
hormonal system. Björntorp’s hypothesis of the neuroendocrine mediation of stress in 
somatic disease through HPAA stimulation, and sympathetic nervous activation of 
autonomic  nervous  system  (ANS),  were  proposed  to  explain  the  morbidity  associated  
with stress (Björntorp et al., 1999). The ANS has two components: the parasympathetic 
nervous system, which controls involuntary resting functions (activation of this system 
promotes digestion and slows heart rate, e.g.), and the sympathetic nervous system, 
which comes into play in threatening situations and results in increases in involuntary 
processes (e.g., heart rate and respiration) that are required to respond to physical 
threats. These specific changes are believed to have evolved to support the behaviors 
that  allow the  organism to  deal  with  the  threat  (e.g.,  to  fight  or  flee).  In  order  for  the  
organism to respond efficiently, physiological systems that are needed to deal with 
threats are mobilized and physiological systems that are not needed are suppressed. 
Psychological stress results in endocrine abnormalities, including high cortisol and low 
sex steroid levels that antagonize the actions of insulin. These mediators subserve 
functions that help the individual during short-term stress. In addition, this hormonal 
24 
 
imbalance causes visceral adiposity, which plays an important role in diabetes and 
cardiovascular disease by contributing to the development of IR (Björntorp, 1991; 
Björntorp et al., 1999). Figure 2 shows the reaction to stress in HPAA resulting in IR. 
 
 
Figure 1. Schematic overview of neuroendocrine mechanisms for IR. Normal regulation: corticotropin 
releasing hormone (CRH) from the hypothalamic region stimulates adrenocorticotropic hormone (ACTH) 
from the pituitary, which in turn drives cortisol secretion from the adrenals. This is controlled by central 
glucocorticoid receptors (GR). With elevated stress this HPAA is activated by central stressors. Elevated 
cortisol induces IR. Abnormal regulation: the HPAA activity is `burned-out', presumably by prolonged 
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stress activation, resulting in low cortisol secretion. Gonadotropin and growth hormone releasing 
hormones (GnRH and GHRH) become inactivated, resulting in low sex steroid and growth hormone (GH) 
secretions. The central sympathetic nervous system becomes activated, resulting in elevated blood 
pressure, heart rate and free fatty acids. Low sex steroid and growth hormones and elevated free fatty 
acids become responsible for IR. With a dysfunction of the central GR this presumed development 
becomes more rapid and pronounced. Adapted from (Björntorp et al., 1999) and printed with a permission 
of the copyright holder. 
 
Modern research has confirmed a link between psychosocial factors and T2D. 
Associated with T2D or risk factors for T2D, among the most studied psychological 
phenotypes are anxiety, early life traumas and post traumatic stress syndrome 
(Agyemang, Goosen, Anujuo, & Ogedegbe, 2011; Sepa, Wahlberg, Vaarala, Frodi, & 
Ludvigsson, 2005; Skilton, Moulin, Terra, & Bonnet, 2007; Thernlund et al., 1995). In 
addition,  personality  factors  such  as  the  Big  Five  personality  traits  that  are  stable  and  
relatively unchanged even in adulthood (Rantanen, Metsäpelto, Feldt, Pulkkinen, & 
Kokko, 2007) have been associated with depression (Jylhä & Isometsä, 2006; Kendler, 
Kuhn, & Prescott, 2004) and with risk factors for T2D (Sutin et al., 2010; Sutin, 
Terracciano et al., 2010). In addition, research on temperament traits have, for example, 
found that anger temperament is associated with increased risk for T2D (Golden et al., 
2006).  
In this thesis the focus is on depressive symptoms, poor sleep quality and stress that 
may be associated with IR, insulin secretion, and MetS – central features of and 
predisposing factors to T2D.  
 
1.3.1. Depressive symptoms 
 
Apart from T2D, major depression is the 4th leading contributor to the global burden of 
disease in 2000 according to the WHO, and is projected to reach 2nd place calculated 
for all ages and both sexes by 2030 (World Health Organization, 2008). Furthermore, 
depression is the leading cause of disability as measured by years of life lost index 
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(World Health Organization, 2008). Several studies in US have found that 3% of men 
and 5–9% of women suffer from clinical depression (Gavard, Lustman, & Clouse, 1993; 
Regier et al., 1993). More recently, prevalence of 6.7% for major depression diagnosed 
with DSM-IV (American Psychiatric Association, 2000) was reported when both sexes 
were combined (Kessler, Chiu, Demler, Merikangas, & Walters, 2005). In a Finnish 
population, a recent study by A. M. Aalto, Elovainio, Kivimäki, Uutela, & Pirkola 
(2012) reported that among persons aged 30 to 79 years, 8% of women and 4% of men 
had had a depressive disorder during the previous 12 months diagnosed with Composite 
International Diagnostic Interview (World Health Organization, 1997). Subclinical 
depressive symptoms, on the other hand, are more common (Anderson, Freedland, 
Clouse, & Lustman, 2001); however, there is no generally accepted method of 
quantifying subclinical symptoms of depression, and consequently many studies have 
used cutoffs based on sensitivity and specificity analyses against clinically defined 
major depression (Beck, Steer, Ball, & Ranieri, 1996; Radloff, 1977), percentile cutoffs 
(25% or 10% of all participants) to identify individuals with the highest levels of 
depressive symptoms, or have used the depressive symptoms’ scores as a linear 
variable. 
Depression is a burden to society when co-occurring with diabetes. The presence of 
major depression disorder in diabetic patients results in symptom amplification, that is, 
even when controlling for severity of diabetes, diabetic patients with co-morbid 
depression experience more symptoms associated with their diabetes than their 
nondepressed counterparts (Ciechanowski, Katon, Russo, & Hirsch, 2003). To illustrate 
this in health care expenditures, one US study found that depressed patients with 
diabetes have higher expenditures (247 million dollars) compared with nondepressed 
patients with diabetes (55 million dollars) (Egede, Zheng, & Simpson, 2002). Similar 
studies are not available in the Finnish population, but in 2010 45 million Euros were 
reimbursed by the Finnish Social Insurance Institution of antidepressant medication use 
and some 150 million was used on reimbursements for diabetes medicines (Social 
Insurance Institution of Finland, 2011). 
Mounting evidence exists indicating that depression is indeed associated with 
diabetes. One meta-analysis including 42 studies found that major depression and 
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elevated depression symptoms were present, respectively, in 11% and 31% of 
individuals with diabetes (Anderson et al., 2001). In addition, one meta-analysis of nine 
longitudinal studies showed that adults with depression or higher levels of depressive 
symptoms have a 37% higher risk of developing T2D (Knol et al., 2006), while another 
meta-analysis found that depression was associated with as high as a 60% increased risk 
for T2D (Mezuk, Eaton, Albrecht, & Golden, 2008). However, there are also studies 
representing a reverse causality. One systematic review and meta-analysis of 11 studies 
showed that overall people with T2D have a 24% increased risk for incident depression 
compared with people without diabetes (Nouwen et al., 2010). Yet, one recent meta-
analysis found that the risk of depression is similar for those with normal and IGT and 
undiagnosed diabetes, thus suggesting that, actually, the diabetes diagnosis per se is a 
burden to an individual (Nouwen et al., 2011). This result could be regarded as support 
for the “psychological burden hypothesis” (Talbot & Nouwen, 2000), which states that 
the burden of knowing that you have diabetes and having a chronic illness to manage, or 
complications to cope with, contributes to higher levels of depression.  
The reason why depression co-occurs and may increase one’s risk for T2D is not 
fully understood. Behavioral or lifestyle factors may offer one explanation. First, 
depressed individuals are less likely to comply with dietary and weight loss 
recommendations (Marcus, Wing, Guare, Blair, & Jawad, 1992) and are more likely to 
be physically inactive (Arroyo et al., 2004; Carnethon, Kinder, Fair, Stafford, & 
Fortmann, 2003; Carnethon et al., 2007; Engum, 2007; Everson-Rose et al., 2004; 
Golden et al., 2004), contributing to obesity, a strong risk factor. Depressed individuals 
have higher caloric intake (Golden et al., 2004), are less physically active and are more 
likely to be smokers (Carnethon et al., 2003; Carnethon et al., 2007; Engum, 2007; 
Everson-Rose et al., 2004; Golden et al., 2004). Furthermore, alcohol consumption 
contributes clearly to development of depression (Boden & Fergusson, 2011). In 
addition, prior studies have shown that depressive symptoms were associated with 
diabetes complications, such as nephropathy (de Groot, Anderson, Freedland, Clouse, & 
Lustman, 2001), retinopathy (Cohen, Welch, Jacobson, De Groot, & Samson, 1997; 
Miyaoka, Miyaoka, Motomiya, Kitamura, & Asai, 1997), neuropathy (Geringer, 
Perlmuter, Stern, & Nathan, 1988; Viinamäki, Niskanen, & Uusitupa, 1995), and 
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macrovascular disease adding to subjective burden (S. A. Black, 1999; Winocour, Main, 
Medlicott, & Anderson, 1990). 
In conclusion, association of depressive symptoms with T2D is well-established, but 
findings regarding conditions and dysfunctions prior to manifest T2D, IR and the MetS, 
are inconclusive.  
 
1.3.1.1 Epidemiological evidence associating depressive symptoms with IR and 
the MetS 
 
Recent evidence suggests that depression affects individuals at all stages of the diabetes 
continuum,  i.e.  IFG,  IGT and  IR.  In  a  cross-sectional  setting, Timonen et al. (2006 & 
2007) have conducted two studies in Finnish samples. First, they observed in a 
population of 2609 men and women that IR was positively associated with current 
severe depression after controlling for BMI (Timonen et al., 2006). They also found 
similar results in another study, but the size of the association was stronger among 1054 
young male Finnish military conscripts and remained after adjusting for waist 
circumference (Timonen et al., 2007). Although large, this study sample was not 
representative of the general population in terms of gender, age, ethnicity, or 
occupational characteristics. Pan et al. (2008) reported similar findings in a Chinese 
population of 3285 participants, showing that depressive symptoms were associated 
with IR after adjusting for BMI. Furthermore, Holt et al. (2009) found that among 1579 
men, IR was significantly associated with depressive scores, but not with insulin 
secretion. However, association with IR was not present in 1418 women. In addition, 
Pearson et al. (2010) found a positive association in a young (26-36 years) population of 
1732 participants, with waist circumference being a mediator. Furthermore, one of the 
first observational studies was the British Women’s Heart and Health study of 4286 
women 60 to 79 years of age randomly selected from primary care. The prevalence of 
depression decreased linearly with increasing IR in women without diabetes (Lawlor, 
Smith, Ebrahim, & British Women's Heart and Health Study, 2003). This cross-
sectional analysis demonstrated a possible protective effect of IR against depression.  
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Golden et al., (2007), Roos et al., (2007) and Qiuhua, Bergquist-Beringer, & Sousa 
(2011) all found no association between depression and IR in their cross-sectional 
analyses. The Multiethnic Study of Atherosclerosis study had the largest sample of 
6754, with high generalizability due to that sample consisted of both genders and 
various ethnicities (Golden et al., 2007). The study by Roos et al. (2007) examined the 
association between depression and IR in 1047 Swedish women. This study concluded 
that depressive symptoms were instead related to lifestyle factors and abdominal 
obesity.  Qiuhua  et  al.  (2011)  analyzed data from the National Health and Nutrition 
Examination Survey and concluded that major depressive disorder was not associated 
with IR. However, a significant gender-by-depression interaction was observed 
indicating that depression was negatively associated with IR in men. One of the 
strengths of this study was its population-based sample, although the nested subsample 
of 637 individuals only identified 16 men and 18 women with major depressive 
disorder, and the study may have been underpowered.  
Only few longitudinal studies have focused on associations of depressive symptoms 
with IR. The study by Lawlor et al. (2005) followed up 2203 Welsh males at 3 time 
points over 14 years and assessed depressive symptoms. In univariate analyses, the 
authors  did  not  find  an  association  between  depression  and  IR  or  BMI.  The  Study  of  
Women’s Health Across the Nation followed 2662 women from the main ethnic groups 
in the United States over 3 years and measured IR (Everson-Rose et al., 2004). 
Depressive symptoms were significantly associated with IR but this disappeared after 
adjusting for waist circumference.  
The findings discussed here showed that the association of depressive symptoms 
with IR may be positive, null or even inverse, and also several methodological issues 
are raised. One of them being the role of antidepressant medication as it has been used 
as an indicator of depression (Lawlor et al., 2003). This  is  due  to  feasibility  of  
antidepressant medication as an alternative for large register studies. A known limitation 
is that antidepressant medication can be used for other conditions than depression, such 
as anxiety disorders, post-traumatic stress disorder or pain, and a specific issue in 
persons with diabetes is the common use of antidepressants for neuropathic pain 
(Gardarsdottir, Heerdink, van Dijk, & Egberts, 2007; Manderbacka, Sund, Koski, 
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Keskimaki, & Elovainio, 2011). The study by Lawlor et al. (2003) had results in conflict 
with other studies mentioned above and it may be because they used antidepressant 
medication as an indicator of depression. This is not only problematic due to 
antidepressant medication being used to treat a variety of disorders other than 
depression, but to mechanisms related to weight gain and hyperglycaemia.  
Indeed, there is strong evidence suggesting that especially tricyclic antidepressants 
(TCA) have independent effects on diabetes risk factors, such as weight gain (Aronne & 
Segal, 2003). Especially conventional antidepressant medications exert disparate effects 
on metabolic physiology. In most cases, these alterations are detrimental, however, in 
some cases, they are salutary. As an example of effects of antidepressant medication, 
several studies exist showing that fluoxetine, a selective serotonin reuptake inhibitor 
(SSRI), exerts a favourable effect on insulin sensitivity and glucose handling in both 
diabetic and mood disorder populations (Ghaeli et al., 2004; Maheux, Ducros, Bourque, 
Garon, & Chiasson, 1997; O'Kane, Wiles, & Wales, 1994; Potter van Loon et al., 1992). 
Amytriptyline and paroxetine have also showed an increase in insulin sensitivity in a 
non-diabetic sample (Weber-Hamann, Gilles, Lederbogen, Heuser, & Deuschle, 2006), 
however, also null findings exist with these medications (Kopf et al., 2004). Citalopram 
has showed no effect to glucose utilization (Kauffman, Castracane, White, Baldock, & 
Owens, 2005). In addition, Chen, Lin, Chen, Mao, & Hung (2010) found null findings 
of fluoxetine and tetracyclic antidepressant mirtatzapine on insulin sensitivity. 
However, mirtazapine has previously been associated with weight gain (Himmerich et 
al., 2006). Duloxetine may increase fasting blood glucose levels in select populations 
(i.e. diabetic peripheral neuropathic pain) (Hardy, Sachson, Shen, Armbruster, & 
Boulton, 2007; Wernicke et al., 2007). Venlafaxine, bupropion, moclobemide, 
trazodone and nefazodone are not known to consistently exert a detrimental effect on 
glucose handling (Moosa, Panz, Jeenah, & Joffe, 2003; Okamura et al., 2000; 
Vanderkooy, Kennedy, & Bagby, 2002; Weber-Hamann et al., 2006). TCAs that 
primarily  target  serotonin  signalling  pathways  (i.e.  tertiary  amines),  in  the  absence  of  
weight gain, are not known to exert an effect on glucose homeostasis, while 
noradrenergic-based TCAs (i.e. secondary amines) are associated with an increase in 
plasma glucose levels (Andersohn, Schade, Suissa, & Garbe, 2009; Moosa et al., 2003; 
Okamura et al., 2000; Weber-Hamann et al., 2006). 
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In addition to associations with IR, depression and sub-clinical depressive symptoms 
have been associated with the MetS – a risk factor for T2D. In a cross-sectional setting, 
Kinder, Carnethon, Palaniappan, King, & Fortmann (2004) found among 3003 non-
diabetic  women  with  a  history  of  a  major  depressive  episode  that  they  were  twice  as  
likely to have the MetS compared with those with no history of depression. 
Furthermore, Toker, Shirom, & Melamed (2008) found that depression among 1525 
women, but not among 2355 men, was associated with an increased prevalence of MetS, 
and with an elevated prevalence of having two of its five components: elevated waist 
circumference and elevated glucose levels, suggesting disturbance in glucose 
metabolism.  Valtonen  et  al.  (2008)  showed in  a  cross-sectional  setting  that  1743 non-
diabetic men with high levels of hopelessness were twice more likely to have MetS than 
men who were less hopeless, independently of a traditional risk factor, body mass index 
(BMI). In addition, there are also findings regarding both sexes. In both men and 
women (n = 1598), MetS was associated with an increased prevalence of depression 
(Skilton et al., 2007). The same has been observed in 867 participants over 65 years of 
age (Vogelzangs et al., 2007) and in a middle-aged Finnish population of 2820 
participants with non-melancholic depressive symptoms (Seppälä et al., 2012).  
In a longitudinal setting, Pulkki-Råback et al. (2009) found that in 538 women, 
depressive symptoms were associated with increased risk for MetS in adulthood. In 383 
men, no associations were found between depressive symptoms and the MetS (Pulkki-
Råback et al., 2009). In addition, Vaccarino et al. (2008), Räikkönen, Matthews, & 
Kuller (2007) and Vanhala, Jokelainen, Keinänen-Kiukaanniemi, Kumpusalo, & 
Koponen (2009)  found among women (n for women at baseline = 652, 541 and 294, 
respectively) that depressive symptoms were associated with an increased risk for MetS. 
In addition, one prospective study found that major depression significantly increases 
the risk for MetS in 429 middle-aged women but the associations were attenuated when 
alcohol consumption was added to the models (Goldbacher, Bromberger, & Matthews, 
2009). 
Representing an opposite direction of causality, Akbaraly et al. (2009) found in a 
longitudinal setting among 5232 middle-aged participants, that MetS at baseline 
predicted future depressive symptoms by five of MetS components, namely central 
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obesity, high triglyceride levels, and low high density lipoprotein (HDL) cholesterol 
levels. Later the authors showed that MetS also increases depressive symptoms in 4446 
elderly  participants,  over  65  years  of  age  as  well  (Akbaraly  et  al.,  2011).  Same  
observation of direction of causality has also been made in Finland regarding 688 
middle-aged participants (Koponen, Jokelainen, Keinänen-Kiukaanniemi, Kumpusalo, 
& Vanhala, 2008). They found that nondepressed women and men with MetS at 
baseline were twice as likely to have depressive symptoms as compared with the 
nondepressed cohort members without MetS after a 7-year follow-up (Koponen et al., 
2008). In addition, MetS in childhood has been found to predict higher levels of 
depressive symptoms in adulthood (Pulkki-Råback et al., 2009). To summarize, the 
direction of causality regarding depressive symptoms and MetS has been under scrutiny 
and recent consensus is that they might actually be both a cause and a consequence 
(Golden et al., 2008; Pan et al., 2012; Räikkönen, Matthews, & Kuller, 2002) 
In addition, one longitudinal study reported that the use of TCA and SSRI 
medications may decrease insulin sensitivity and increase the risk for T2D (L. C. 
Brown, Majumdar, & Johnson, 2008). Indeed, apart from methodological differences, 
such as age- and gender distribution of the study sample and different methods for 
measuring depressive symptoms, the controversial findings regarding MetS and IR may 
arise from differences in the use of antidepressant medication between the studied 
populations. One recent study (Rubin et al., 2008) found that antidepressant medication 
was a stronger predictor of MetS than depressive symptoms, indicating that the 
association between depressive symptoms and MetS might be driven by antidepressant 
medication. 
In conclusion, findings of associations between depressive symptoms with IR and 
MetS are inconclusive and a mixed pattern of results has been presented. Furthermore, 
knowledge of diagnosis for T2D, or the manifest disease per se, might affect the 
associations of depressive symptoms with IR and the MetS, and lastly, antidepressant 
medication might by a causative factor behind these associations.  
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1.3.2 Poor sleep quality 
 
Changes in modern society include longer working hours, more shift-work, and 
continuous availability of commodities. These changes are paralleled by secular trends 
of curtailed duration of sleep to fewer hours per day across westernized populations 
(Akerstedt & Nilsson, 2003). Consequently, increasing number of people are reporting 
sleep complaints including insomnia, that is, difficulty falling asleep or staying asleep, 
and daytime sleepiness (Bliwise, 1996; Ohayon, 2008a; Roth et al., 2011). At the same 
time, sleep apnea is also highly prevalent in western society (D. E. Ford & Kamerow, 
1989; Ohayon & Partinen, 2002). As a result, sleep complaints can have important 
consequences for sufferers and may impact on health, work, and quality of life. Such 
associations include increased use of health care services (Leger, Guilleminault, Bader, 
Levy, & Paillard, 2002; Weyerer & Dilling, 1991) and a higher risk of motor vehicle 
accidents (Ohayon & Smirne, 2002). In addition, studies looking at the relationship 
between insomnia and work have found associations with absenteeism, decreased 
concentration, impaired work performance and work related accidents (Leger et al., 
2002; Linton & Bryngelsson, 2000). Thus, poor sleep quality represents another burden 
to individuals and to society. 
An estimated 33% of adults in Western countries experience signs of insomnia 
(LeBlanc et al., 2009; Morphy, Dunn, Lewis, Boardman, & Croft, 2007; M. B. Stein, 
Belik, Jacobi, & Sareen, 2008). However, much of this variation in prevalence may be 
explained by the use of different definitions of insomnia in these studies (Ohayon, 
2002). In United Kingdom, Morphy et al. (2007) found among 2363 participants that 
37% had subjective insomnia complaints and this was strongly associated with 
depression.  In  United  States  as  part  of  the  National  Institute  of  Mental  Health  
Epidemiologic Catchment Area study, 7954 respondents were questioned about sleep 
complaints and psychiatric symptoms using the Diagnostic Interview Schedule (Robins, 
Helzer, Croghan, Williams, & Spitzer, 1981). Of this community sample, 10.2% and 
3.2% noted insomnia and hypersomnia, that is, excessive sleepiness or prolonged sleep 
duration, respectively (D. E. Ford & Kamerow, 1989). However, a more recent study 
conducted by the America Insomnia Survey, an epidemiological survey of managed 
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health care plan subscribers (n = 10,094), showed that insomnia prevalence estimates 
varied widely, from 22.1% by The Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition text revision (DSM-IV) (American Psychiatric Association, 
2000) criteria, to 3.9% by International Statistical Classification of Diseases, Tenth 
Revision (ICD-10) (World Health Organization, 1991) criteria (Roth et al., 2011). In 
addition to this, one systematic review found that the prevalence of subjective sleep 
complaints regarding excessive daytime sleepiness occurring at least 3 days per week 
has been reported in between 4% and 20.6% of the population, while severe excessive 
daytime sleepiness was reported by 5% (Ohayon, 2002).  
Hublin, Kaprio, Partinen, Heikkilä, & Koskenvuo (1996) found in a large cross-
sectional study of 11,354 Finnish participants that 11.0% of women and 6.7% of men 
suffered from daytime sleepiness every or almost every day. Amongst those with 
sleepiness (n = 1026) 19.5% of women and 42.3% of men reported snoring three or 
more nights per week, 25% had scores suggesting moderate to severe depression, 11% 
used hypnotics or tranquilizers, and 9% reported insufficient sleep. Insomnia at least 
every other day was reported by 20.7% of women and by 28.6% of men (Hublin et al., 
1996). In another study in the general Finnish population, the overall prevalence of 
insomnia symptoms occurring at least three nights per week was 37.6% (Ohayon & 
Partinen, 2002). Difficulty initiating sleep was mentioned by 11.9%, difficulty 
maintaining sleep by 31.6%, early morning awakenings by 11.0% and non-restorative 
sleep by 7.9% of participants. Furthermore, the authors were able to diagnose insomnia 
according to DSM-IV criteria, and found the prevalence was 11.7%. As a conclusion, 
compared with other European countries studied with the same methodology (France, 
the United Kingdom, Germany, and Italy), the prevalence of insomnia diagnosed with 
DSM-IV was 1.5 to two times higher in Finland (Ohayon & Partinen, 2002). In 
addition, a US study found that of the 1506 participants, 26% (31% of men and 21% of 
women) assessed with the Berlin questionnaire (Netzer, Stoohs, Netzer, Clark, & Strohl, 
1999) indicated a high risk of sleep apnea (Hiestand, Britz, Goldman, & Phillips, 2006). 
A Finnish study by Renko, Hiltunen, Laakso, Rajala, & Keinänen-Kiukaanniemi (2005) 
found among 593 men and women that 25.8% of all subjects were habitual snorers and 
no gender differences were found. In addition, the prevalence of sleep apnea, derived 
from a self-report questionnaire, in the whole sample was 4.3%.  
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Apart from actual diagnosis based on DSM-IV or ICD-10, and due to differences in 
methods of assessing subjective sleep complaints, the exact prevalence rates for 
subjective sleep complaints are difficult to derive. However, subjective sleep 
complaints, representing also the undiagnosed cases with sleep disorders, are more 
common than clinically diagnosed sleep disorders (Ohayon & Partinen, 2002).  
Over the past two decades both prospective and cross-sectional studies have 
demonstrated that poor sleep, defined as abnormal sleep duration or poor subjective 
sleep quality, is a risk factor for T2D (Cappuccio, D'Elia, Strazzullo, & Miller, 2010). 
Strong body of evidence shows that a U-shaped association exists between sleep 
duration and prevalence of T2D indicating that both short sleep duration, that is 
reflected in complaints of insomnia and consequently in daytime sleepiness; and long 
sleep  duration  -  a  possible  sign  of  depression,  pose  a  risk  for  T2D  (Cappuccio  et  al.,  
2010; D. E. Ford & Kamerow, 1989). In more detail, Nilsson, Roost, Engstrom, 
Hedblad, & Berglund (2004) found in a longitudinal setting over an average 15 year 
follow-up time that difficulties in falling asleep or regular use of hypnotics were 
associated with development of T2D when full adjustments were made for baseline age, 
biological risk factors, lifestyle, family history of diabetes, and social class. 
Furthermore, Meisinger, Heier, Loewel, & MONICA/KORA Augsburg Cohort Study 
(2005) found similar results indicating that difficulty maintaining sleep was associated 
with an increased risk for T2D in men and women from the general population. Mallon, 
Broman, & Hetta (2005) on the other hand found that difficulties maintaining sleep or 
short sleep duration (< 5h) were associated with an increased incidence of T2D in men 
over a 12 year follow-up. As a conclusion, the review/meta-analysis by Cappuccio et al. 
(2010) concluded that the risk for T2D varies between 28% in people who report 
habitual sleep of less than six hours per night and 84% in those with difficulties in 
maintaining their sleep. 
Showing the opposite direction of causality, T2D has been associated with increased 
frequency of sleep complaints (Gislason & Almqvist, 1987; Hyyppä & Kronholm, 
1989; Resnick et al., 2003; Sridhar & Madhu, 1994). This may, though, be due to the 
disease itself as well as to physical complications of the disease (Sridhar & Madhu, 
1994). However, poor sleep may also play a primary role in the pathophysiology of 
T2D. Several studies have demonstrated that individuals suffering from poor sleep have 
36 
 
increased physiological activation (M. H. Bonnet & Arand, 1997; M. H. Bonnet & 
Arand, 1998; M. H. Bonnet & Arand, 2000; Broman & Hetta, 1994; Pavlova et al., 
2001; Shaver, Johnston, Lentz, & Landis, 2002). Evidence from studies of adult 
samples also indicate that insufficient sleep is a contributing factor for obesity and for 
altered glucose metabolism (Ayas et al., 2003; Gottlieb et al., 2005; Knutson & Van 
Cauter, 2008; Mallon et al., 2005). Lack of sleep exerts deleterious effects on a variety 
of systems with detectable changes in metabolic (Knutson, Spiegel, Penev, & Van 
Cauter, 2007; Spiegel, Tasali, Leproult, & Van Cauter, 2009), endocrine (Spiegel, 
Knutson, Leproult, Tasali, & Van Cauter, 2005), and immune pathways (M. A. Miller & 
Cappuccio, 2007).  
There are many factors that may contribute to poor sleep and result in subjective 
sleep complaints. Apart from changes in society, the most commonly hypothesized 
predisposing factors include demographic factors (e.g., aging, female gender, living 
alone) (Ancoli-Israel & Roth, 1999; Mellinger, Balter, & Uhlenhuth, 1985; Ohayon, 
2002), familial/hereditary conditions (a personal or family history of insomnia) (Bastien 
& Morin, 2000; Dauvilliers et al., 2005; Hauri & Olmstead, 1980) and physiological 
and lifestyle factors (e.g., arousability, smoking and alcohol consumption) (Coren, 
1988; Phillips & Danner, 1995; M. D. Stein & Friedmann, 2005). Precipitating factors 
include psychological and health-related factors (e.g., pain, mental health problems) (C. 
M. Morin, 1993; C. M. Morin, Rodrigue, & Ivers, 2003), and depression (D. E. Ford & 
Kamerow, 1989; Hublin et al., 1996; LeBlanc et al., 2009; Morphy et al., 2007; Ohayon, 
2002; Ohayon, 2008b). In addition, although there are multiple established factors that 
predispose to sleep apnea, excess weight is the strongest (Hiestand et al., 2006; Young, 
Peppard, & Taheri, 2005). About 70% of people with sleep apnea are obese, and 
conversely, the prevalence of the disorder among obese people is approximately 40% 
(Akinnusi, Saliba, Porhomayon, & El-Solh, 2012). 
While these findings suggest that sleep complaints may be associated with T2D, the 
evidence with respect to IR and insulin secretion, two major features of T2D, in 
individuals without T2D has been scarce and elusive.  
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1.3.2.1 Epidemiological evidence of poor sleep associating with IR 
 
Not only is poor sleep an independent risk factor for T2D, but experimental studies in 
healthy individuals without diabetes have shown that restriction of sleep duration and 
restriction of duration of restorative slow-wave-sleep without changing the total sleep 
duration are associated with IR during hyperinsulinaemic clamp conditions (Donga et 
al., 2010) or during an IVGTT (Buxton et al., 2010; Spiegel, Leproult, & Van Cauter, 
1999). Therefore, the impact of sleep restriction on glucose regulation suggests a 
mechanism whereby short sleep time, as manifesting in complaints of insomnia and 
daytime sleepiness, might increase the risk for T2D by increasing IR (Buxton et al., 
2010; Spiegel et al., 1999; Vgontzas et al., 1999). Indeed, short-term, acute, laboratory, 
and cross-sectional observational studies conclude that disturbed or reduced sleep is 
associated with glucose intolerance, IR, reduced acute insulin response to glucose, and 
with a reduction in the disposition index showing a defect in insulin secretion (Spiegel 
et al., 2009). Conversely, observational studies in individuals without diabetes have also 
shown prolonged sleep duration, postulated to be a marker of underlying co-morbidity, 
also  has  been  identified  to  be  a  risk  factor  for  a  number  of  adverse  health  outcomes,  
including IGT (Gottlieb et al., 2005) and the MetS (Hall et al., 2008). There is also 
evidence that short sleep duration predicts IFG over time (Rafalson et al., 2010). 
However, the evidence remains mixed as (Chao et al., 2011) found that both short and 
long sleep duration were not associated with prediabetes, defined as a sum of IFG and 
IGT.  
Furthermore, sleep apnea, including sleep disordered breathing and habitual snoring, 
has been associated with IFG, IGT and IR. Experimental studies in individuals without 
a history of or concurrently diagnosed T2D have showed that polysomnography-based 
sleep disordered breathing was associated with IFG, IGT (Seicean et al., 2008), higher 
frequency of IR (Punjabi et al., 2002; Punjabi et al., 2004) and decreased degree of 
insulin sensitivity and pancreatic beta-cell function during a frequently sampled IVGTT 
(Punjabi & Beamer, 2009). Yet, in a Finnish study subjective complaints of sleep apnea, 
habitual snoring and daytime sleepiness were not associated with IFG, IGT and IR 
(Renko et al., 2005). In addition, a recent study reported among participants free of 
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diabetes that subjective complaints of frequent snoring and insomnia were not 
associated  with  fasting  insulin  and  glucose  levels  and  IR  (Knutson,  Van  Cauter,  Zee,  
Liu, & Lauderdale, 2011).  
In conclusion, sleep apnea, insomnia and daytime sleepiness, may contribute to IR, 
but evidence is scarce and elusive. Lastly, accumulating cross-sectional and longitudinal 
evidence also suggests that depression is a significant correlate of sleep duration (Patel, 
Malhotra, Gottlieb, White, & Hu, 2006; Perlman, Johnson, & Mellman, 2006) and of 
sleep complaints (Barcelo et al., 2008; Hublin et al., 1996; LeBlanc et al., 2009; Morphy 
et al., 2007; Ohayon, Caulet, & Lemoine, 1998), and must therefore be taken into count 
when assessing the independent associations of sleep complaints and dysfunctions in 
glucose regulation. Finally, although sleep complaints often co-occur (Barcelo et al., 
2008; Healey et al., 1981; Ohayon & Partinen, 2002; Ohayon, 2002), to my knowledge, 
there are no other studies that have assessed the associations of co-morbid sleep 
complaints and IR. 
 
1.3.3 Stress 
 
Modern society imposes demands on many that lead to difficulties in coping with their 
situations and this may lead to a state of chronic stress. Living organisms survive by 
maintaining an immensely complex dynamic and harmonious equilibrium, or 
homeostasis, that is constantly challenged or outright threatened by intrinsic or extrinsic 
disturbing forces or stressors (Chrousos & Gold, 1992). The concept of stress has been 
developed in the 1930s by the Hungarian endocrinologist Hans Selye. Selye (1950) 
defined stress as “the nonspecific response of the body to any demand,” with the body 
going through three universal stages of dealing with the stressor: the alarm phase (“fight 
or flight”), the resistance phase (in which resistance to the stress is built), and the 
exhaustion phase (when the duration of stress is sufficiently long), together 
encompassing the “general adaptation syndrome”. One can also define stress as a 
stimulus, either internal or external, that activates the HPAA and the sympathetic 
nervous system, resulting in a physiological change or adaptation so that the organism 
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can deal with the threat (Björntorp, 1991; Björntorp, 1997). Defense reactions involve 
catecholamine release, vagal withdrawal, cortisol secretion, and activation of the renin-
angiotensin system; the less well characterized defeat reaction is a stimulus for cortisol 
production (Folkow, 1997; Henry & Grim, 1990). These mediators subserve functions 
that help the individual during short-term stress. When stressor is frequent, adaptation 
(coping) is lacking, the ability to shut off the stress response is deficient, or the 
responses to stress are inadequate and compensatory mechanisms are activated, the 
allostatic load may become overwhelming and the adaptive processes become 
maladaptive (McEwen, 1998). 
In the 1960’s, Holmes and Rahe published work on stressful life events and 
indentified stressors such as “death of spouse”, “divorce”, “death of a close family 
member”, “personal injury”, “laid off from work”, that are consistently rated among the 
most severe occurrences during an individual lifetime (Brugha, Bebbington, Tennant, & 
Hurry, 1985; Chandola, Brunner, & Marmot, 2006; Rahe, Bennett, Romo, Siltanen, & 
Arthur, 1973). Ever since, the same domains of stressors continue to be seen in 
research: work, finance, health, social and housing (Brugha et al., 1985; Chandola et al., 
2006; Healey et al., 1981; Mooy, de Vries, Grootenhuis, Bouter, & Heine, 2000). Since 
these are subjective experiences, usually stressful life experiences are measured with 
questionnaires. Any stressful event might be judged by people in different ways, based 
on factors such as previous experience, psychological factors, and social influences. An 
event that is seen by one individual as particularly threatening might be seen as totally 
harmless by another individual. Prevalence rates are difficult to assess as stressful life 
events usually occur unexpected and the reactions and coping to these events differ by 
individual. 
Evidence of stress contributing to onset of diabetes derives from laboratory studies in 
animals (Surwit, Schneider, & Feinglos, 1992; Wales, 1995). However, on human 
samples, only a modest amount of epidemiological literature on the effects of stressful 
life  events  on  diabetes  has  accumulated  over  the  past  40  years.  In  the  Hoorn  study,  
Mooy et al. (2000) found in a cross-sectional setting among 2262 participants that 
stressful life events, which indicate chronic psychological stress, were associated with 
undetected T2D and with visceral adiposity. Furthermore, the authors found that the 
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accumulation of stressful life events was associated with an increased prevalence of 
T2D. However, in this white middle-aged population, visceral adiposity did not seem to 
be the main link between stress and diabetes, and the associations of single stressful life 
events with T2D were weak. Only death of a partner and moving the place of residence 
were significantly associated with T2D (Mooy et al., 2000). Additionally, psychosocial 
stress at workplace has most consistently been associated with T2D. In three Swedish 
studies (the Stockholm Diabetes Prevention Program, Vasterbotten Intervention 
Programme, and the Belstress study), job strain was associated with a higher prevalence 
of T2D among women (Agardh et al., 2003; Leynen et al., 2003; Norberg et al., 2007). 
However, the design of these studies was not prospective and the direction of causality 
remains open. 
Few longitudinal studies show that stressful life events are associated with T2D. 
Rod, Gronbaek, Schnohr, Prescott, & Kristensen (2009) analyzed data from the 
Copenhagen City Heart Study, involving 7066 women and men, and found that stressed 
men, but not women, were more than two times as likely to develop T2D during follow-
up. Interestingly, participants who had reported high levels of stress compared to those 
with  low  levels  of  stress  were  less  likely  to  quit  smoking,  more  likely  to  become  
physically inactive, and less likely to stop drinking during follow-up: all these factors 
are known to be associated with an increased risk for T2D and could mediate the link 
between stress and onset of T2D. In a Japanese community-based cohort study, the 
associations between perceived mental stress and the onset of diabetes were investigated 
(Kato et al., 2009). A total of 55,826 subjects (24,826 men and 31,000 women) aged 40-
69 years were followed for 10 years. A self-administered questionnaire on medical 
conditions including diabetes and other lifestyle factors was completed at baseline and 5 
and 10 years later. Like the Copenhagen City Heart Study, the risk for T2D increased 
with an increasing stress level, especially among men. In another Japanese study by 
Toshihiro et al. (2008) among 128 male Japanese with impaired glucose metabolism, a 
high score on a questionnaire assessing “stress in daily life” was associated with the 
development of T2D after a 3-year follow-up. Furthermore, in a large population-based 
sample of 33,336 participants, tense working situation related working stress was 
associated with onset of diabetes after, on average, 5 years, in women, but not in men 
(Norberg et al., 2007). In addition, burn-out, resulting from chronic work stress, has also 
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been studied as a risk factor for the development of T2D. In a longitudinal study among 
677 employed men and women, a high level of baseline burn-out symptoms was 
associated with the development of T2D (Melamed, Shirom, Toker, & Shapira, 2006). 
In the Whitehall II Study, the investigators tested whether stress at work was associated 
with an increased risk for T2D in a sample of 5895 middle aged civil servants 
(Heraclides, Chandola, Witte, & Brunner, 2009). In that study, psychosocial stress at 
work appeared to be an independent predictor of the onset of T2D among women, 
during a follow-up period of 15 years, but not in men. Finally, also a null finding has 
been reported. In the Whitehall II Study Kumari, Head, & Marmot (2004) found that 
men and women who reported to have experienced two or more stressful life events 
tended to have an increased risk of diabetes, though both associations were statistically 
not significant.  
Stressful  life  events  can  increase  the  risk  for  T2D through different  pathways.  The  
first pathway is via behavioral mechanisms. Emotional stress has been associated with 
unhealthy lifestyle behaviors, i.e., inadequate eating behaviors in terms of quality and 
quantity of food, low exercise levels, smoking and alcohol abuse (Björntorp, 1993; F. 
Bonnet  et  al.,  2005;  Lloyd  et  al.,  2010;  Rod  et  al.,  2009).  All  these  factors  are  well-
known risk factors for the development of T2D. The second pathway is via 
physiological mechanisms, e.g. abnormal HPAA activation as introduced earlier in this 
summary.  
Taken together, these studies implicate that stressful life events may associate with 
T2D. However, there is scarce epidemiological support available for the hypothesis that 
stressful life events are associated with IR and MetS, conditions prior to manifest T2D.  
 
1.3.3.1 Epidemiological evidence of stressful life events associating with IR and 
the MetS 
 
Only few studies have shown association between stressful life events and the MetS. 
Vogelzangs et al. (2007) found in their cross-sectional cohort study of 2917 elderly men 
and women that per each experienced negative life event the odds for having MetS 
increased by 13 percent: Negative life events and inadequate emotional support 
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increased the odds of having MetS after adjustment for demographic and lifestyle 
variables.  More  recently,  Horri  et  al.  (2010)  found  in  a  cross-sectional  setting  among  
351 middle-aged women who were first-degree relatives of T2D that participants 
experiencing  eight  or  more  stressful  life  events  were  more  likely  to  have  MetS.  In  
addition, while studies of stressful life events and MetS may implicate an association 
between stress and IR, only Zhang et al. (2006) have studied the association of stress 
and IR in participants without diabetes. They analyzed data from 643 non-diabetic men 
with a mean age of 63 years, and found that persons who reported a high level of stress 
and high hostility were more likely to be insulin resistant. However, this study sample 
of Normative Aging Study consisted of volunteers aged 63 years, and thus the results 
may not apply to a younger population. 
Few longitudinal studies have associated stress with MetS. In a small sample of 
elderly women and men caregivers’ stress predicted MetS at follow-up over 15 later: 
caregiver men had a greater prevalence of coronary heart disease (CHD) than did 
noncaregiver men 27 to 30 months after study entry (Vitaliano et al., 2002). This was 
influenced by pathways from caregiving to distress, distress to the MetS, and MetS to 
CHD. In the Whitehall II study including over 10,000 middle-aged civil servants, 
chronic work stress predicted higher odds for having MetS at follow-up 14 years later: 
A dose-response relationship was found between exposure to work stressors over 14 
years  and  risk  of  MetS,  independent  of  other  relevant  risk  factors  (Chandola  et  al.,  
2006). Employees with chronic work stress (three or more exposures) were more than 
twice  as  likely  to  have  MetS  than  those  without  work  related  stress.  In  the  Pittsburgh  
Healthy Women Study middle-aged women who experienced life events as extremely 
stressful had an increased risk for developing MetS over an average 15 years of follow-
up:  among  women  who  did  not  have  MetS  at  the  baseline,  the  risk  for  the  syndrome  
varied from 1.21- to 2.12-fold for more severe depressive symptoms or very stressful 
life  event(s)  (Räikkönen  et  al.,  2007).  These  associations  were  largely  the  same,  
regardless of the clinical criteria used to define MetS. Those who at baseline reported 
feeling frequently and intensely angry, tense, or stressed also had an increased risk for 
developing MetS. In the same study also marital dissatisfaction, divorce, and 
widowhood predicted an increased risk for developing MetS over an average follow-up 
of 11.5 years: compared with maritally satisfied women, martially dissatisfied and 
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widowed women were significantly more likely to have the MetS at follow-up (Troxel, 
Matthews, Gallo, & Kuller, 2005).  
To summarize, limited evidence exists showing a link between stressful life events 
and  IR  and  MetS.  While  important,  none  of  the  studies  regarding  risk  factors  for  or  
components of (MetS or IR) T2D so far have been population-based restricting the 
external validity of the findings: the participants have been recruited from health care 
beneficiaries  (Vogelzangs  et  al.,  2007),  from  Alzheimer’s  caregivers  (Vitaliano  et  al.,  
2002), from employees of civil service departments (Chandola et al., 2006), from 
initially healthy premenopausal women holding a driver’s licence (Räikkönen et al., 
2007; Troxel et al., 2005), women who were already at genetic risk for T2D (Horri et 
al., 2010) or participants who were of late middle-age volunteers and of good health 
(Zhang et al., 2006). Clearly population-based studies comprising all age groups and 
both sexes are needed. 
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2 AIMS OF THE STUDY 
 
The aim to this thesis is to assess whether psychosocial risk factors are associated with 
IR and insulin secretion in individuals without T2D. In order to achieve this aim, the 
following more specific research questions were addressed: 
 
i) This study examined whether depressive symptoms are associated with IR 
and insulin secretion, and examined whether these associations are driven by 
the use of antidepressant medication. 
 
ii) This study also examined whether poor sleep quality as reflected in 
subjective complaints of sleep apnea, daytime sleepiness and insomnia, and 
the accumulation of the often co-occurring sleep complaints are associated 
with IR and insulin secretion.  
 
iii) Further, this study examined whether stressful life events arising from 
various life domains, and their accumulation, are associated with IR and 
insulin secretion. 
 
iv) Finally, this study examined whether depressive symptoms and stressful life 
events are associated with the MetS  
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3 METHODS 
 
3.1 Outline of the PPP-Botnia Study 
 
This thesis consists of four studies conducted with the PPP-Botnia Study (Prevalence, 
Prediction and Prevention of diabetes). The PPP-Botnia Study is a population-based 
study in the Botnia region of Western Finland. The study is designed to obtain accurate 
estimates  of  prevalence  and  risk  factors  for  diabetes,  IGT  and  the  MetS  in  the  
population aged 18–75 years and to use this information for prediction and prevention 
of the disease. The current study was initiated in 2004 in 5 Botnia centres (Närpes, 
Malax-Korsnäs, Korsholm, Vasa and Jakobstad) comprising a total population of 
135,000 persons. Using the population registry we selected an age-adjusted random 
sample of subjects aged 18 to 75 years (96,000 subjects) representing on average 9% of 
the population; in the age groups 18-29 and 60-75 years this represented 10% and in the 
age group 30-59 years 7% of the eligible population. Of the 9518 invited individuals 
5208 (2443 men and 2765 women) (55 %) participated. The participants gave their 
written informed consent. The study protocol has been approved by the ethics 
committee of Helsinki University Hospital. 
The subjects participated in an OGTT by ingesting 75 g of glucose after a 12-h 
overnight  fast.  Subjects  with  known  diabetes  and  on  anti-diabetic  medication  or  with  
fasting plasma glucose >10 mmol/l did not take part in the OGTT (n = 19). During the 
OGTT samples for plasma glucose and insulin were drawn at 0, 30 and 120 min. 
Diagnosis  of  diabetes  was  based  on  the  results  from  the  OGTT  or  a  history  of  
previously known diabetes. In uncertain cases, the diagnosis was confirmed from 
patient records. The diagnosis of diabetes and cut-offs for IFG and IGT were based on 
the WHO criteria (Alberti & Zimmet, 1998). Fasting blood samples were drawn for the 
measurement of serum total cholesterol, HDL cholesterol and triglycerides. Plasma 
glucose during the OGTT was measured with a glucose dehydrogenase method 
(Hemocue, Angelholm, Sweden) and serum insulin by a fluoroimmunoassay (Delphia, 
Perkin-Elmer Finland, Turku, Finland). Serum HDL cholesterol and triglyceride 
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concentrations were analysed with an enzymatic method on a Konelab 60i analyser 
(Thermo Electron Oy, Vantaa, Finland).  
Waist circumference was measured by a research nurse with a soft tape on standing 
subjects midway between the lowest rib and the iliac crest. Two blood pressure 
recordings  were  obtained  from the  right  arm in  a  sitting  position  after  10  min  of  rest,  
and the mean value was calculated. In addition, participants were asked to fill in a 
questionnaire on psychosocial measures and trained nurses collected data on 
background information and medications. During 2007-2009 a subpopulation recruited 
from Vasa area was studied and a psychological questionnaire was sent by post. Figure 
2 shows a flowchart of the study and study samples. 
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Figure 2. Flowchart showing the participants in PPP-Botnia study. In every study, the maximum number 
of participants with full data on psychosocial measures and outcome measures were used. 
  
3.2 Study samples 
 
Table 3 shows the characteristics of the total study sample. In every study the maximum 
number of available participants with full data on psychosocial measures and outcome 
measures were used. 
 
 
 
9518 18-75 year old subjects were invited
to PPP-Botnia study
Data 
collection
began
2007 and 
finished
2009
In 2009: 5208 (55%) had participated
Study II: A subpopulation from Vasa, 796
participants with full data on sleep
complaints and IR
Study IV: Data 
collected by
2007. 3407
participants
with full data 
on stressful life 
events and IR 
and MetS
Study I: 4419 participants free of diabetes 
and with full data on depressive symptoms
and IR
Study III: 4967 participants with full data 
on depressive symptoms and MetS
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Table 3. Characteristics of the PPP-study study (n = 5208). 
Sex, women, n (%) 2765 (53.1) 
Age (years) 49.6 ± 15.7 
Insulin (mU/L)  
   Fasting    7.1 ± 7.7 
   120 min 35.0 ± 38.8 
   Area Under the Curve (mU/L/120 min.) 5223.7 ± 3451.6 
Glucose  (mmol/L)    
   Fasting    5.4 ± 0.9 
   120 min  5.5 ± 2.2 
   Area Under the Curve (mmol/L/120 min.) 835.7 ± 185.9 
HOMAIR 1.8 ± 2.3 
ISI 9.0 ± 5.6 
CIR 189.0 ± 178.7 
DI 1538.7 ± 1719.2 
Triglycerides (mmol/L) 1.3 ± 0.8 
HDL cholesterol (mmol/L)  
   men 1.2 ± 0.3 
   women 1.5 ± 0.4 
Systolic blood pressure (mmHg) 133.6 ± 19.4 
Diastolic blood pressure (mmHg) 80.6 ± 10.1 
Body Mass Index (kg/m2) 26.5 ± 4.5 
Waist circumference (cm)  
   men 95.3 ± 11.4 
   women 84.2 ± 12.5 
Current smoker,  n (%) 767 (14.9) 
Regular exercise,  n (%) 2,797 (54.9) 
Alcohol consumption, n (%)   
   None 1,370 (27.4) 
   12-48 g/wk 2,287 (45.7) 
   60 ? g/wk 1,350 (27.0) 
Occupational status, n (%)      
   Senior Clerical  844 (16.6) 
   Junior Clerical  1,462 (28.7) 
   Manual Worker  1,295 (25.4) 
   Retired 1,270 (24.9) 
   Student 221 (4.2) 
1st degree family history for diabetes, n (%) 1576 (33.6) 
Note. Data are mean ± standard deviation (SD), unless otherwise indicated. Current smoking 
status was determined if participant reported using tobacco products (yes vs. no or former use). 
Based upon leisure-time activity self-reported in a questionnaire, the participants were assigned 
into two groups: if they performed more than 30 minutes physical activity three or more times 
per week with an intensity resulting in breathlessness and/or sweating they were assigned to 
regularly exercising group (yes), and if they performed less or performed no activity they were 
assigned to less/no exercising group (no).  Alchohol dose per week was converted to grams per 
week.  
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3.2.1 Study I 
 
Of the 5208 participants, 206 individuals with previously and 122 with newly diagnosed 
diabetes were excluded, as were 29 individuals using antipsychotic medication, and 5 
using lithium, as the use of these medications might alter glucose metabolism. This 
resulted in a sample of 4419 participants (2095 men and 2324 women) with complete 
data available on depressive symptoms and indices of IR. Those with incomplete data (n 
= 427) were older, were more likely to be retired, and consumed less alcohol as 
compared to those with complete data (p < 0.005).  
 
3.2.2 Study II 
 
Of those who participated in the PPP-Botnia study, 2232 belonged to a sub-population 
who were recruited from the Vasa area. A psychological survey including a 
questionnaire on subjective sleep complaints was added later to the study protocol and 
administered to 1335 individuals of the Vasa sub-population. 1066 (79.9%) returned the 
questionnaire and 949 (535 women and 414 men) provided complete data on all 
subjective sleep complaints. Of them 47 had a previously and 24 a newly diagnosed 
diabetes and 82 had incomplete data on IR, and were thus excluded. In total, 796 
participants (442 women and 354 men) without diabetes had complete data available on 
sleep complaints and indices of IR and insulin secretion. These participants differed  
from the entire PPP-Botnia sample without diabetes (n = 3885 after excluding 257 with 
previous/new diabetes) by being older, more frequently retired, had higher fasting and 
120 min glucose during an OGTT, consumed more alcohol and reported  regular 
exercise more frequently. 
 
3.2.3 Study III 
 
Of the 5208 participants, 4967 (2336 men and 2631 women) had complete data 
available on the components of the MetS, the use of antidepressant medication and 
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depressive symptoms, and did not use antipsychotic medication (n = 36) or lithium (n = 
5). Those with incomplete data (n = 200) were older, more frequently retired, consumed 
less alcohol, had higher glucose concentrations (fasting and 2-hour glucose) and higher 
systolic blood pressure (SBP) levels, larger waist circumference, higher triglycerides 
and reported more frequently a family history of diabetes than compared with those 
with complete data. The study included participants with and without diabetes and 
cardiovascular disease (CVD). 
Participants filled in a standardized health questionnaire covering information 
regarding history of CHD (including myocardial infarction, coronary bypass surgery 
and percutaneous coronary interventions), and stroke (including both ischemic and 
hemorrhagic stroke) and invasive procedures for peripheral arterial disease. 
Cardiovascular disease (CVD) was considered present if any of these manifestations 
were present. Those with established diabetes or CVD (n = 539), in comparison to the 
other participants with no such disease, were older, more frequently men and retired, 
had the MetS more frequently, had a higher fasting glucose, 2-h glucose, waist 
circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP), 
triglycerides, and lower HDL cholesterol, consumed less alcohol, reported more 
frequently a family history for diabetes and had higher depressive symptoms scores (all 
P-values < 0.008; data not shown). 
 
3.2.4 Study IV 
 
Study IV was carried out with the data collected until 2007; the first 3621 persons (1712 
men and 1899 women) of the 6079 invited at that time. Of the 3621 participants, 17 had 
missing information on at least one of the components of the MetS, and 192 did not fill 
in the stressful life events questionnaire. Altogether, 3407 (1618 men and 1789 women) 
subjects had complete data available on the components of MetS and stressful life 
events. They were younger and more educated, reported higher alcohol intake, had less 
often a family history for diabetes and met the criteria for MetS less often compared to 
the entire group (P < .001; no differences were found in sex distribution or frequency of 
smoking and regular exercise, p-values > 0.31). Finally, participants of study IV (n = 
51 
 
3407) differed from participants whose data was not yet collected by the end of 2007 (n 
= 1801) by being younger, their fasting and 120 min glucose and BMI was lower, 
systolic BP was higher, they exercised less, and they were more likely employed. 
 
3.3 Definitions for IR and insulin secretion, Studies I, II & IV 
 
Based  on  values  obtained  from  the  OGTT,  HOMAIR, (Matthews et al., 1985), ISI 
(Bergman et al., 1987), CIR (Hanson et al., 2000; Lyssenko et al., 2008) and DI 
(Bergman et al., 2002) were calculated and used as indices of IR and insulin secretion. 
In addition, AUC insulin and glucose, were used as additional surrogate indices of IR. 
The formulas for these indices were presented in Introduction (please see Table 2, page 
19). 
 
3.4 Definitions for the MetS, Studies III & IV 
 
In the current study, three different definitions for MetS were used: the harmonized 
criteria (Alberti et al., 2009), the ATP III (Grundy et al., 2005; National Cholesterol 
Education  Program  (NCEP)  Expert  Panel  on  Detection,  Evaluation,  and  Treatment  of  
High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002) and the IDF 
criteria (Alberti et al., 2005). In study III, the harmonized clinical criteria for the MetS 
was used (Alberti et al., 2009). Accordingly, the definition of MetS requires that at least 
three of the following five criteria have to be met: fasting plasma glucose (? 5.6 mmol/l 
and/or diabetes medication), triglycerides (? 1.7 mmol/l and/or drug treatment of high 
triglycerides), HDL cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women 
and/or  drug  treatment  for  low  HDL  cholesterol),  blood  pressure  (? 130/85 mmHg 
and/or use of anti-hypertensive medication), and waist circumference (ethnicity- and 
country-specific cut-off; we used the European Cardiovascular Society’s cut-offs, ? 102 
cm for men and ? 88 cm for women (Graham et al.,  2007)).  In study IV, the ATP III  
and the IDF clinical criteria were used. According to the ATP III criteria at least three of 
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the following five criteria have to be met: waist circumference ? 102 cm in men and 
?88 cm in women, serum triglycerides ? 1.7 mmol/l and HDL -cholesterol < 1.0 mmol/l 
in men and < 1.3 mmol/l in women, IFG/IGT or diabetes, and blood pressure ? 130/85 
mmHg and/or use of anti-hypertensive medication. The IDF clinical criteria include 
waist circumference ? 94 cm in men and ? 80 cm in women and an additional two of 
the following criteria: serum triglycerides ? 1.7 mmol/l, HDL cholesterol < 1.03 mmol/l 
in men and < 1.29 mmol/l in women, blood pressure (? 130/85 mmHg and/or use of 
anti-hypertensive medication) or fasting plasma glucose ? 5.6 mmol/l.  
 
3.5 Psychosocial measures 
 
3.5.1 Depressive symptoms and use of antidepressant medication, 
Studies I & III 
 
Depressive symptoms refer to wide range of mental problems, including emotional, 
cognitive, behavioral and physical symptoms. Most epidemiological studies use self-
report questionnaires to assess depressive symptoms and to identify persons with 
perceived mental stress. Self-reports are less expensive and less time-consuming than 
interviews and therefore more practical for research use. In order to measure depressive 
symptoms in studies I & III, participants filled in the SF-36/RAND-36 questionnaire 
(Hays, Sherbourne, & Mazel, 1993) containing nine items of depressive symptoms. The 
Mental Health Index (MHI), a subscale of SF-36, is used to capture four major 
dimensions of mental health: anxiety, depression, loss of behavioral/emotional control, 
and psychological well-being (Hays et al., 1993), and the scale has been shown to have 
high sensitivity and specificity for detecting clinical depression (Berwick et al., 1991). 
However, a Finnish validation study of SF-36 found that the Vitality Scale (VS) items 
correlate positively with MHI, and concluded that the VS items are also important in 
capturing depression in a Finnish population (A. Aalto, Aro, & Teperi, 1999). A similar 
observation has been made in a French population (Perneger, Leplege, Etter, & 
Rougemont, 1995). Therefore, items of the MHI and the VS were summed (after reverse 
scoring the positive items) to measure depressive symptoms on a scale asking 
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participants how much of the time during the preceding four weeks they felt full of life, 
nervous, happy, calm and peaceful, worn out, full of energy, downhearted and blue, 
tired, or so down nothing could cheer them up. The items were rated on a six-point scale 
(not at all, on very few occasions, some of the time, good part of the time, most of the 
time, all of the time). The reliability for these items was high (Cronbach’s ? = 0.89) and 
a factor analysis (using an eigenvalue criterion of one) of the items supported a 
unidimensional,  single-scale  solution  (data  not  shown).  MHI  and  VS  were  also  
significantly correlated (r = 0.70, P < 0.001). When using the sum variable in analysis, it 
was standardized according to sex and log-transformed.  
The use of antidepressant medication was self-reported in a questionnaire and 
confirmed in an interview by a research nurse specifying the type of medication they 
used. In study I, when participants with either established or newly diagnosed diabetes 
(diagnosis based on OGTT) were excluded, the number of participants using 
antidepressant medication was: SSRI/SNRI medication (n = 98), TCA medication (n = 
36), TCA and SSRI/SNRI medication (n = 10), and antidepressant medication not 
specified (n = 3) as an indicator of use of antidepressant medication (n = 147, 110 
women and 37 men). In study III, current use of SSRI/SNRI medication (n = 116), TCA 
medication (n = 43), and TCA and SSRI/SNRI (n = 11) were considered as an indicator 
of use of antidepressant medication. In addition, information on 4 participants’ type of 
medication was insufficient. In total 174 participants, 132 women and 42 men, reported 
using one or more products of antidepressant medication.  
 
3.5.2 Subjective sleep complaints, Study II 
 
Complaints related to sleep apnea, insomnia and daytime sleepiness were derived from 
the self-reported questionnaire, the Basic Nordic Sleep Questionnaire (BNSQ) (Partinen 
& Gislason, 1995). The following three questions addressed sleep apnea: 1. Do you 
snore  while  sleep  (ask  other  people  if  you  do  not  know)?  2.  How  do  you  snore  (ask  
other people about the quality of your snoring)? 3. Have you had breathing pauses at 
sleep (have other people noticed that you have pauses in your respiration when you 
sleep)?  The following three questions addressed insomnia: 1. Have you had difficulties 
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in falling asleep the past three months?, 2. How often have you awakened during the 
night the past three months?, 3. If you use to wake up during the night, how many times 
do you usually wake up during one night (during the past three months)? Daytime 
sleepiness was measured with the following three questions: 1. Do you feel excessively 
sleepy in the morning after awakening? 2. Do you feel excessively sleepy during 
daytime?  3. How often do you sleep naps at daytime?  
The questions were answered by using a quantitative scale ranging from never or less 
than once per month (1), less than once per week (2), on one-two days/nights per week 
(3), on three-five days/nights per week (4) to  every day/night or almost every day/night 
per week (5); except, the quality of snoring was assessed using a qualitative scale 
ranging from “I don’t snore” (1), “my snoring sounds regular and it is of low voice” (2),  
“it sounds regular, but rather loud” (3), “it sounds regular but very loud (other people 
hear my snoring in the next room)” (4) to “I snore very loud and intermittently (there 
are silent breathing pauses when snoring is not heard and at times very loud snorts with 
gasping)” (5), and frequency of awakenings during one night was assessed using a 
quantitative scale ranging from usually “I do not wake up at night” (1), once per night 
(2), two times (3), three-four times (4) to at least five times per night (5).  
Answers to questions on sleep apnea, insomnia and daytime sleepiness were summed 
and the top quartile was used as a cut-off for identifying individuals with more frequent/ 
severe complaints. The group whose complaints of sleep apnea, insomnia and daytime 
sleepiness fell below the top quartile and who in addition reported using no sleeping 
pills ( 9.4%, n = 75, reported using sleeping pills) was used as the reference group (from 
here on referred to as ‘No or minor sleep complaints’). 
 
3.5.3 Stressful life events, Study IV 
 
The subjects completed a questionnaire consisting of 15 stressful life events (Table 4). 
All questions concerned life events known to be major stressors (Brugha et al., 1985; 
Mooy et al., 2000; Rahe et al., 1973; Räikkönen et al., 2007). The subjects were asked 
to evaluate the occurrence and stressfulness of these events (0 = not occurred, 1 = not at 
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all stressful, 2 = mildly stressful, 3 = moderately stressful, 4= extremely stressful) 
during the past 12 months. For the analyses, the measurement scale was dichotomized 
by contrasting moderately and extremely stressful events with events that were not at all 
or mildly stressful or had not occurred at all (Räikkönen et al., 2007). These items 
encompassed stressful events arising from five different domains: finance, work, social 
relationships, health and housing. Reliability of these items measured with the 
Cronbach’s ? was 0.76. 
 
Table 4. Items of stressful life events questionnaire and their domains. 
 
3.6 Mediating and confounding factors  
 
Selection of confounding factors was based on previous studies as discussed earlier in 
this thesis. Participants self-reported in a questionnaire their weekly alcohol 
consumption  (g/week  or  dose/week),  current  smoking  status  (yes  vs.  no  or  former  
smoker), occupational status (categorized according to the classification system of 
Statistics Finland: manual workers, junior clericals, senior clericals, students, and 
retirees; http://kanta.stat.fi:8080/exist/rest/db/Apps/LuokitusEkspertti/query.xq) and 
Finance 
1. Ongoing financial strain 
2. Severe financial strain,  laid off business 
3. Threat of unemployment or personal bankruptcy 
Work 
4. Continuous work overload 
5. Troubles with co–workers 
6. Began a new job  
Social relationships 
7. Ongoing difficulties in close relationships 
8. Divorced or separated from husband/wife/partner  
9. Death of spouse/partner/close friend  
Health 
10. Serious injury or illness  
11. Concern over health of a family member or a close friend 
12. Concern over own or child’s ability to cope with stress 
Housing 
13. Loss of home 
14. Change of residence  
15. Difficulties in housing  
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family history of known diabetes (yes vs. no) in at least one first degree relative (father, 
mother or sibling). Instead of using occupational status as a confounder in study IV, 
level of education (less than high school, high school or college graduate, degree 
beyond college) was used as a confounder in statistical analysis. In addition, frequency 
and intensity of current physical activity and physical activity during the past 12 months 
were assessed using the validated Kuopio Ischemic Heart Disease Questionnaire 
(Salonen & Lakka, 1987). This questionnaire provides detailed information on common 
lifestyle, commuting and leisure-time physical activity and enables assessment of total 
physical activity as metabolic equivalent (MET) hours per week (MET × hours/week). 
Based upon leisure-time activity, the participants were assigned into two groups: if they 
performed more than 30 minutes physical activity three or more times per week with an 
intensity resulting in breathlessness and/or sweating they were assigned to regularly 
exercising group (yes), and if they performed less or performed no activity they were 
assigned to less/no exercising group (no). In addition, a research nurse measured body 
weight  and  height  with  subjects  in  light  indoor  clothing  and  without  shoes.  BMI  was  
calculated as weight (kg) divided by height (m) squared and it was used as a confounder 
in studies I and II. Furthermore, in study II, depressive symptoms were self-rated using 
the Beck Depression Inventory II (Beck et al., 1996). Logarithmic transformation was 
applied to the scale. 
 
3.7 Statistical analysis 
 
3.7.1 Study I 
 
Multiple linear regression analyses, unstandardized regression coefficients and 95% 
Confidence Intervals (95% CI) were computed to examine associations between 
depressive symptoms and use of antidepressant medication with fasting, 30 and 120 min 
glucose and insulin. Logistic regression analyses, odds ratios (OR) and 95% Confidence 
Intervals (CI) were computed to examine if depressive symptoms and use of 
antidepressant medication were associated with HOMAIR,  and  CIR.  Indices  of  IR and  
insulin secretion were dichotomized such that the top quartile in the HOMAIR was 
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contrasted with the lower three quartiles and the bottom quartile of CIR were contrasted 
with the upper three quartiles. For those analyses that tested if any potential associations 
between depressive symptoms with the indices of IR and insulin secretion were altered 
by use of antidepressant medication, individuals reporting use of antidepressant 
medication were excluded and the analyses were re-run. Variables were log-transformed 
where appropriate and the associations were adjusted for the mediating and confounding 
factors.  
Finally, because associations between depressive symptoms, use of antidepressant 
medication and the IR have varied between men and women (Lawlor et al., 2003; 
Lawlor  et  al.,  2005),  and  since  these  data  demonstrated  that  women  scored  higher  on  
depressive symptoms (p < 0.01; data not shown) and reported more frequent use of 
antidepressant medication (p < 0.01), it was tested if any of the associations varied by 
sex by including an interaction term, ‘sex × depressive symptoms/use of antidepressant 
medication’ in the models. In no instance was there a significant sex - interaction –term 
(p values > 0.26) (data not shown). For this reason we report the results with sexes 
combined. 
 
3.7.2 Study II 
 
Multiple linear regression analyses, unstandardized regression coefficients and 95% CI 
were computed to examine associations between sleep complaints and fasting, 120 min 
and AUC glucose and insulin. Logistic regression analyses, OR and 95% CI were 
computed to examine if sleep complaints were associated with HOMAIR, ISI, CIR and 
DI. Indices of IR and insulin secretion were dichotomized such that the top quartile in 
the HOMAIR was contrasted with the lower three quartiles and the bottom quartiles in 
the ISI, CIR and DI were contrasted with the upper three quartiles. Variables were log-
transformed where appropriate and the associations were adjusted for the mediating and 
confounding factors.  
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3.7.3 Study III 
 
Logistic regression analyses, OR and 95% CI were computed to examine if depressive 
symptoms and antidepressant medication use were associated with MetS. Multiple 
linear regression analyses, unstandardized regression coefficients and 95% CI were 
computed to examine associations between depressive symptoms and antidepressant 
medication use with fasting and 2-h plasma glucose, triglycerides, HDL cholesterol, 
waist circumference and SBP and DBP. For those analyses that tested if any potential 
associations between depressive symptoms with MetS and its individual components 
were secondary to antidepressant medication use, individuals reporting antidepressant 
medication  use  were  excluded  and  the  analyses  were  re-run.  This  was  the  chosen  
approach because antidepressant medication and depression symptoms were correlated. 
Variables were log-transformed where appropriate. The associations were adjusted 
for mediating and confounding factors. The associations were re-run after excluding 
participants with established diabetes and CVD.  
Finally, because associations between depressive symptoms, antidepressant 
medication use and MetS may be moderated by sex (Kinder et al., 2004; Toker et al., 
2008; Vaccarino et al., 2008; Vanhala et al., 2009), and since these data demonstrated 
that women scored higher on depressive symptoms (p < 0.01; data not shown) and 
reported more frequent use of antidepressant medication (p < 0.01), it tested if any of 
the associations varied for men and women by including an interaction term, ‘sex × 
depressive symptoms/antidepressant medication use’ in the models. In no instance was 
there  a  significant  sex  -  interaction  –term  (p  values  >  0.38;  data  not  shown).  For  this  
reason the results were reported with sexes combined. 
 
3.7.4 Study IV 
 
Logistic  regression  analyses,  OR and  95% CI  were  computed  to  examine  associations  
between stressful life events and the MetS. Multiple linear regression analyses, 
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unstandardized regression coefficients and 95% CI were computed to examine 
associations between stressful life events and HOMAIR, waist circumference, BMI, 
triglycerides, HDL cholesterol, SBP and DBP, and logistic regression analyses to 
examine associations with IFG and IGT. The associations were adjusted for the 
mediating and confounding factors. Since the unadjusted and fully adjusted models 
resulted in essentially similar results, the fully adjusted associations were presented. 
Finally, because associations between psychosocial factors and the MetS may be 
moderated by sex (Vitaliano et al., 2002; Vogelzangs et al., 2007), it was tested if any of 
the associations varied for men and women by including an interaction term, ‘sex × 
extremely stressful life event’ in the models. In no instance, was there a significant sex - 
interaction –term (p-values > .07; data not shown). For this reason we report the results 
with sexes combined. 
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4 RESULTS 
 
4.1 Study I: Are depressive symptoms associated with IR and 
insulin secretion?  
 
Depressive symptoms were associated with increased odds for antidepressant 
medication use (Total score: OR = 2.64, 95% CI, 2.22, 3.13; MHI: OR = 2.42, 95% CI, 
2.05, 2.85; VS: OR = 2.52, 95% CI, 2.10, 3.02 per each SD unit increase in symptoms).  
Antidepressant medication use was significantly associated with higher odds for 
belonging to the top quartile of HOMAIR, but not with CIR (Table 5) or with insulin and 
glucose values during an OGTT (Tables 6 & 7) in models adjusted for confounding and 
mediating factors. 
Table 5 shows that even after adjusting for confounding and mediating factors, 
depressive symptoms were associated with higher odds for belonging to the top quartile 
of HOMAIR and with higher fasting and 30 min insulin values (Table 6), but did not 
associate with the CIR in any of the models (Table 5). 
Analyses addressing interactions between antidepressant medication use and 
depressive symptoms showed that depressive symptoms were associated with higher 
120-minute glucose in participants using antidepressants (Total score: 5.6% increase, 
95% CI, 0.8, 10.5, P = 0.02; VS: 5.9% increase, 95% CI, 0.08, 11.0, P = 0.02, per SD 
unit increase in symptoms). In contrast, the associations were not significant in those 
not using antidepressants (P-values > 0.24) (P-values < 0.05 for ‘antidepressant 
medication use × depressive symptoms’-interactions). There were no further significant 
interactions. 
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Table 5. Associations between depressive symptoms, use of antidepressant medication and 
HOMAIR and CIR as indices of IR and insulin secretion. 
 HOMAIR a  CIR b  
 Odds ratio p Odds ratio p 
Depression: (95% CI)  (95% CI)  
Antidepressant      
medication (no vs. yes) c     
  Sex and age adjusted model 1.82 (1.29–2.58) 0.001 1.21 (0.83–1.76) 0.320 
  Full model d  1.66 (1.11–2.48) 0.014 1.36 (0.92–2.01) 0.121 
Depressive symptoms      
Total Score (SD units)     
  Sex and age adjusted model 1.17 (1.09–1.25) 0.001 0.99 (0.92–1.06) 0.681 
  Full model d 1.12 (1.03–1.21) 0.007 0.98 (0.91–1.06) 0.679 
Mental Health Index (SD units)     
  Sex and age adjusted model 1.11 (1.04–1.19) 0.003 0.99 (0.93–1.07) 0.848 
  Full model d 1.09 (1.01–1.18) 0.038 0.99 (0.92–1.07) 0.810 
Vitality Scale (SD units)     
  Sex and age adjusted model 1.20 (1.12–1.29) 0.001 0.98 (0.91–1.05) 0.496 
  Full model d 1.13 (1.04–1.22) 0.004 0.98 (0.91–1.06) 0.580 
Note. a HOMAIR was dichotomized contrasting the highest quartile (referent) with the other 
three quartiles, n = 1105 vs. 3314; b CIR was dichotomized contrasting the lowest quartile 
(referent) with the other three quartiles, n = 1104 vs. 3315; c Number of individuals using 
antidepressant medication is 147; d Full model refers to adjustments for age, sex, regular 
exercise (yes, more than 30 minutes intense physical activity >3 times per week resulting in 
breathlessness/sweating vs. no, less or no activity), alcohol consumption (g/week), current 
smoking status (yes vs. no or former smoker), BMI (kg/m2), occupational status (manual 
workers, junior clericals, senior clericals, students, and retirees) and family history of diabetes at 
least in one first degree relative.  
 
Depressive symptoms were significantly associated with higher fasting insulin levels, 
and with higher insulin and glucose levels (30 and 120 min) during the OGTT (Tables 6 
& 7). The associations with fasting and 30 min insulin remained significant in models 
adjusting for confounding and mediating factors and after excluding participants using 
antidepressant medication (Tables 6 & 7). The other associations became non-
significant.  
 
62 
 
Table 6. Associations between depressive symptoms, use of antidepressant medication and 
insulin levels during an OGTT. 
 Fasting  30 min.  120 min.  
Depression: % change  
(95% CI) 
p % change  
(95% CI) 
p % change  
(95% CI) 
p 
Antidepressant        
medication       
(no vs. yes) a       
  Sex and age        
  adjusted model 8.14 (-1.35–17.91) 0.103 6.78 (-2.69–16.25) 0.161 -7.73(-21.20–5.73) 0.260 
    Full model b 1.39 (-7.42–10.19) 0.758 1.23 (-8.00–10.46) 0.794 -13.11  0.051 
     (-26.26–0.04)  
Depressive        
symptoms       
Total Score       
(SD units)       
  Sex and age        
  adjusted model 4.57 (2.81–6.34)  0.001 3.82 (2.11–5.53)  0.001 4.21 (1.76–6.65)  0.001 
  Full model b 2.71 (1.08–4.34)  0.001 2.31 (0.60–4.02) 0.008 1.97 (-0.47–4.40) 0.113 
Mental Health        
Index (SD units)       
  Sex and age        
  adjusted model 3.16 (1.40–4.95)  0.001 2.16 (0.44–3.88)  0.014 2.69 (0.24–5.14)  0.032 
  Full model b 2.05 (0.42–3.67)  0.014 1.21 (-0.50–2.92) 0.165 1.49 (-0.94–3.92) 0.230 
Vitality Scale       
(SD units)       
  Sex and age        
  adjusted model 5.04 (3.28–6.80)  0.001 4.58 (2.87–6.29)  0.001 4.70 (2.27–7.13)  0.001 
  Full model b 2.79 (1.16–4.42)  0.001 2.76 (1.05–4.47) 0.002 1.87 (-0.57–4.30) 0.133 
Note. Insulin and glucose values were log-transformed. a Number of individuals using 
antidepressant medication is 147; b Full model refers to a model adjusting for age, sex, physical 
activity, BMI, alcohol consumption, current smoking status, occupational status and family 
history for diabetes. 
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Table 7. Associations between depressive symptoms, use of antidepressant medication and 
glucose levels during an OGTT. 
 Fasting  30 min.  120 min.  
Depression: % change  
(95% CI) 
p % change  
(95% CI) 
p % change  
(95% CI) 
p 
Antidepressant        
medication       
(no vs. yes) a       
  Sex and age        
  adjusted model 1.26 (-0.48–3.00) 0.156 3.96 (1.04–6.88) 0.008 0.84 (-0.39–5.61) 0.730 
  Full model b 0.83 (-0.96–2.61) 0.362 2.90 (-0.06–5.88) 0.055 -0.97 (-5.79–3.84) 0.691 
Depressive        
symptoms       
Total Score        
(SD units)       
  Sex and age        
  adjusted model -0.03 (-0.35–0.28)  0.830 0.90 (0.37–1.43)  0.001 1.18 (0.31–2.05)  0.007 
  Full model b -0.16 (-0.49–0.17) 0.344 0.34 (-0.20–0.89) 0.221 0.69 (-0.19–1.58) 0.126 
Mental Health        
Index (SD units)       
  Sex and age        
  adjusted model -0.03 (-0.35–0.28)  0.831 0.51 (-0.01–1.05)  0.056 0.83 (-0.04–1.70)  0.061 
  Full model b -0.01 (-0.47–0.19) 0.413 0.08 (-0.46–0.64) 0.752 0.47 (-0.41–1.36) 0.299 
Vitality Scale        
(SD units)       
  Sex and age        
  adjusted model -0.03 (-0.34–0.34)  0.861 1.04 (0.51–1.56)  0.001 1.20 (0.34–2.07)  0.006 
  Full model b -0.15(-0.48–0.18) 0.370 0.46 (-0.09–1.00) 0.104 0.69 (-0.19–1.59) 0.127 
Note. Insulin and glucose values were log-transformed. a Number of individuals using 
antidepressant medication is 147; b Full model refers to a model adjusting for age, sex, physical 
activity, BMI, alcohol consumption, current smoking status, occupational status and family 
history for diabetes. 
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4.2 Study II: Are subjective sleep complaints associated with IR 
and insulin secretion?  
 
Among the individuals who during the past three months reported more frequent/severe 
complaints of sleep apnea (n = 162), 143 (88%) reported snoring at least three nights 
per week, 47 (29%) reported at least very loud and intermittent snoring, and 34 (21%) 
reported breathing pauses at least three nights per week. Of those with more 
frequent/severe insomnia (n = 163), 39 (24%) reported having problems in initiating 
sleep at least three nights per week, 120 (74%) reported waking up every night or 
almost every night per week, and 52 (32%) reported waking up at least three times per 
one night, and of those with more frequent/severe daytime sleepiness (n = 202), 95 
(47%) reported feeling sleepy in the morning at least three days per week, 103 (51%) 
reported feeling sleepy during daytime at least three days per week, and 94 (47%) 
reported having had naps at least three days per week. 
Of the sleep complaints, daytime sleepiness occurred most frequently alone (n = 104, 
40%) followed by sleep apnea (n = 81, 31%) and insomnia (n = 77, 29%). The most 
common combination of two co-occurring complaints was insomnia-daytime sleepiness 
(n = 38, 41%) followed by sleep-apnea-daytime sleepiness (n = 33, 36%) and sleep-
apnea-insomnia (n = 21, 23%). All three sleep complaints were present in only 27 
individuals and thus were not separately analysed.   
Individuals with more frequent complaints of sleep apnea, insomnia and daytime 
sleepiness were older, heavier, more frequently manual workers/retired, more 
depressed, and those with sleep apnea were additionally more frequently men, smoked 
currently and used more alcohol more frequently and exercised regularly less 
frequently. Further, complaints of sleep apnea and insomnia were more frequent in post- 
than pre-menopausal women (data not shown). 
Those with more frequent sleep complaints (sleep apnea, insomnia or daytime 
sleepiness) were significantly more insulin resistant than individuals with none/minor 
subjective sleep complaints as evidenced by higher fasting and 120 min insulin and 
higher 120 min glucose concentrations and higher AUC for insulin and glucose, as well 
as were more likely to have high HOMAIR and low ISI (Table 8). In addition, sleep 
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apnea was associated with lower DI (Table 8). When adjustments were made for  sex 
and age, and further for mediating and confounding factors the associations of sleep 
apnea with fasting insulin and DI, and of insomnia with fasting insulin, 120 min 
glucose, AUC for glucose and HOMAIR and ISI were rendered non-significant (Table 
8). No association was found with insulin secretion. These associations changed only a 
little when further adjustments for depressive symptoms were made (please see 
footnotes of Table 8). 
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Table 8. Associations between subjective sleep complaints and insulin and glucose values during 
an OGTT, and indices of IR and insulin secretion. 
 Sleep complaints, No or minor complaints (n=395)                                                           
vs. More frequent: 
 Sleep apnea (n  = 162) Insomnia (n = 163) Daytime sleepiness  
(n = 202) 
 Mean 
difference,% / 
 Mean  
difference, % / 
 Mean  
difference, % / 
 
 Odds Ratio  Odds Ratio  Odds Ratio  
 (95% CI) p (95% CI) p (95% CI) p 
Insulin       
Fasting       
  Sex and age adjusted 18.6 (7.3–29.9) 0.001 14.0 (3.3–24.7) 0.011 14.9 (5.0–24.8) 0.003 
  Fully adjusted 8.6 (-1.9–19.2) 0.110 4.2 (-5.4–13.8) 0.286 10.4 (1.4–19.3) 0.023 
120 minute        
  Sex and age adjusted 33.1 (17.9–48.3) 0.001 23.5 (9.3–37.7) 0.001 25.2 (11.9–38.5) 0.001 
  Fully adjusted 22.7 (7.4–37.9) 0.004 15.4 (1.2–29.5) 0.034 a 22.4 (9.3–35.4) 0.001 
Area Under the Curve       
  Sex and age adjusted 22.0 (11.5–32.6) 0.001 20.2 (10.2–30.2) 0.001 19.7 (10.5–28.9) 0.001 
  Fully adjusted 13.6 (3.4–23.7) 0.009 12.6 (3.2–22.0) 0.009 16.4 (7.8–25.1) 0.001 
Glucose       
Fasting       
  Sex and age adjusted -0.1 (-1.9–1.6) 0.894 0.5 (-1.2–2.2) 0.553 -0.2 (-1.7–1.4) 0.809 
  Fully adjusted -0.6 (-2.5–1.2) 0.506 0.2 (-1.6–1.9) 0.830 -0.4 (-2.0–1.2) 0.601 
120 minute        
  Sex and age adjusted 8.7 (3.2–14.3) 0.002 4.4 (-0.7–9.5) 0.093 7.0 (2.2–11.8) 0.005 
  Fully adjusted 7.6 (1.7–13.4) 0.011 2.9 (-2.5–8.2) 0.291 6.6 (1.7–11.5) 0.008 
Area Under the Curve       
  Sex and age adjusted 4.6 (1.8–7.3) 0.001 2.5 (-0.1–5.1) 0.056 3.9 (1.5–6.3) 0.001 
  Fully adjusted 2.8 (0.0–5.7) 0.052 b 1.5 (-1.2–4.2) 0.269 3.3 (0.9–5.8) 0.007 
HOMAIR       
  Sex and age adjusted 2.49 (1.63–3.80) 0.001 1.68 (1.09–2.58) 0.018 1.80 (1.22–2.66) 0.003 
  Fully adjusted 2.18 (1.33–3.59) 0.002 1.24 (0.74–2.09) 0.417 1.75 (1.10–2.77) 0.017 
ISI       
  Sex and age adjusted 2.55 (1.67–3.89) 0.001 2.04 (1.33–3.13) 0.001 1.95 (1.31–2.89) 0.001 
  Fully adjusted 2.13 (1.28–3.55) 0.004 1.58 (0.94–2.65) 0.082 b 1.89 (1.18–3.02) 0.008 
CIR       
  Sex and age adjusted 0.82 (0.53–1.27) 0.373 0.72 (0.46–1.14) 0.158 0.76 (0.50–1.14) 0.179 
  Fully adjusted 0.86 (0.54–1.38) 0.526 0.76 (0.47–1.23) 0.261 0.75 (0.49–1.15) 0.184 
DI       
  Sex and age adjusted 1.67 (1.09–2.58) 0.019 0.87 (0.54–1.39) 0.560 1.32 (0.88–2.00) 0.184 
  Fully adjusted 1.24 (0.77–1.99) 0.373 0.69 (0.41–1.14) 0.145 1.16 (0.75–1.81) 0.501 
Note. Fully adjusted refers to a model adjusting for sex, age, alcohol consumption, current 
smoking status, regular exercise, occupational status, BMI and family history for diabetes.              
a Association is not statistically significant when further adjusted for depressive symptoms.           
b Association becomes statistically significant when further adjusted for depressive symptoms. 
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4.2.1 Co-occurrence of sleep complaints and IR and insulin secretion 
 
The likelihood of being insulin resistant, as evidenced by higher fasting and 120 min 
insulin and 120 min glucose concentrations and higher AUC for insulin and glucose, 
and higher likelihood of having high HOMAIR and low ISI increased according to the 
accumulation of co-occurring sleep complaints (Table 9). Figure 3 displays graphically 
the significantly linearly increasing trends of AUC insulin and AUC glucose, and the 
percentage of individuals with high HOMAIR and low ISI according to accumulation of 
co-occurring sleep complaints. These associations remained significant in the fully 
adjusted  models  (Table  9).  No  association  was  found  with  insulin  secretion.  These  
associations changed only little when further adjustments were made for depressive 
symptoms (please see footnotes in Table 9). 
Finally, it was tested if the associations were driven by IFG and/or IGT -associated 
abnormalities in insulin and glucose concentrations. All analyses were re-ran, first, after 
excluding individuals with IGT (n = 55), and, then, after excluding individuals with IFG 
or IGT (n = 166). In the first set of analyses the following associations were rendered 
non-significant: sleep apnea and daytime sleepiness with 120 min glucose, insomnia 
with 120 min insulin, and accumulation of co-occurring sleep complaints with 120 min 
and  AUC  glucose.  In  the  second  set  of  analyses  the  following  additional  associations  
were rendered non-significant: sleep apnea with 120 min and AUC insulin and ISI. The 
other associations remained significant (all P-values < 0.05; data not shown).  
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Table 9. Associations between accumulation of co-occuring subjective sleep complaints and 
insulin and glucose values during an OGTT, and indices of IR and insulin secretion. 
 Sleep complaints, No or minor complaints  (n=395) vs. More 
frequent: 
 One complaint  Two-Three 
complaints 
  
 (n=262)  (n=119)   
 Mean  
difference, % / 
 Mean  
difference, % / 
  
 Odds Ratio  Odds Ratio  p for 
 (95% CI) p (95% CI) p linear 
trend 
Insulin      
Fasting      
        Sex and age adjusted 6.5 (-2.6–15.5) 0.163 25.5 (13.4–37.7) 0.001  
        Fully adjusted 1.1 (-7.1–9.3) 0.789 15.6 (4.5–26.6) 0.006 0.002 
120 minute       
        Sex and age adjusted 18.7 (6.3–31.1) 0.003 34.6 (18.5–50.8) 0.001  
        Fully adjusted 15.4 (3.1–27.8) 0.014 24.9 (8.8–40.9) 0.002 0.001 
Area Under the Curve      
        Sex and age adjusted 14.5 (6.0–23.1) 0.001 26.5 (15.2–37.8) 0.001  
        Fully adjusted 11.0 (2.9–19.2) 0.008 18.0 (7.4–28.7) 0.001 0.001 
Glucose      
Fasting      
        Sex and age adjusted 0.0 (-1.4–1.4) 0.998 0.0 (-1.9–1.9) 0.999  
        Fully adjusted -0.1 (-1.5–1.4) 0.901 -0.6 (-2.6–1.4) 0.557 0.965 
120 minute       
        Sex and age adjusted 4.2 (-0.2–8.7) 0.063 8.1 (2.2–14.0) 0.007  
        Fully adjusted 4.5 (-0.1–9.1) 0.056 a 6.1 (0.0–12.2) 0.049 0.024 
Area Under the Curve      
        Sex and age adjusted 2.1 (0.0–4.3) 0.054 5.2 (2.2–8.3) 0.001  
        Fully adjusted 1.9 (-0.4–4.1) 0.100 3.6 (0.5–6.7) 0.023 0.006 
HOMAIR      
        Sex and age adjusted 1.35 (0.92–1.96) 0.121 2.62 (1.66–4.12) 0.001  
        Fully adjusted 1.23 (0.80–1.91) 0.347 2.17 (1.26–3.71) 0.005 0.001 
ISI      
        Sex and age adjusted 1.52 (1.04–2.21) 0.030 2.87 (1.82–4.52) 0.001  
        Fully adjusted 1.39 (0.89–2.18) 0.147 2.42 (1.40–4.16) 0.001 0.001 
CIR      
        Sex and age adjusted 0.75 (0.52–1.09) 0.133 0.85 (0.53–1.38) 0.508  
        Fully adjusted 0.76 (0.52–1.13) 0.175 0.90 (0.54–1.50) 0.675 0.647 
DI      
        Sex and age adjusted 1.14 (0.77–1.68) 0.508 1.49 (0.92–2.42) 0.105  
        Fully adjusted 0.97 (0.64–1.48) 0.971 1.18 (0.70–1.97) 0.541 0.224 
Note. Fully adjusted refers to a model adjusting for  sex, age, alcohol consumption, current 
smoking status, regular exercise, occupational status, BMI and family history for diabetes.          
a Association becomes statistically significant when further adjusting for depressive symptoms. 
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Figure 3. Geometric means of Area Under the Curve (AUC) of insulin (panel A) and glucose (panel B) 
and adjusted percent of insulin resistant individuals (percent of individuals in the top quartile of 
Homeostasis model assessment method, HOMAIR, (panel C) and in the bottom quartile of Insulin 
Sensitivity Index, ISI, panel D) (adjusted for sex, age. alcohol consumption, current smoking status, 
regular exercise, occupational status,  BMI and family history for diabetes)  and 95% CI (error bars) 
according to accumulation of co-occurring sleep complaints.  
P for linear trend=0.006
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4.3 Study IV: Are stressful life events associated with IR and 
insulin secretion?  
 
In addition to studying the associations of stressful life events with IR when participants 
with T2D were included in the analysis, as presented in Study IV, I will also present 
additional results when participants with manifest diabetes or with T2D diagnosis based 
on OGTT, were excluded.  
 
4.3.1 Are stressful life events associated with IR and IGT? Individuals with 
T2D included. 
 
Results of Study IV indicated that participants who had experienced stressful life events 
in the finance-, work-, and health-related domains or had experienced at least three 
events in any of the life domains displayed higher levels of HOMAIR, and had a higher 
odds for having IGT (Table 10). In addition, participants who had experienced stressful 
life  events  in  the  finance-  and  work-related  domains  or  had  experienced  at  least  three  
events in any of the life domains displayed larger waist circumference, higher BMI and 
higher  triglyceride  levels  (data  not  shown).  Stress  did  not  associate  significantly  with  
IFG, HDL cholesterol or BP (data not shown). Finally, except for accumulation of at 
least one financial stress-related event and accumulation of at least two health-related 
events, the associations remained statistically significant when models were further 
adjusted for depressive symptoms measured with SF-36. 
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Table 10. Fully adjusted (sex, age, alcohol consumption, current smoking status, regular 
exercise, level of education and family history of diabetes) associations between accumulation 
of stressful life events during the past 12 months with IR and IGT. 
   IGT  
 HOMAIR   (no vs. yes)  
No (n = 2296) versus     
accumulation of extremely % change  Odds ratio  
stressful life events: (95% CI) p (95% CI) p 
Finance     
at least 1 event (n= 273) 10.03 (0.40–19.65) 0.041 a 1.71 (0.93–3.16) 0.085 
at least 2 events (n= 98) 24.20 (8.67–39.72) 0.002  3.27 (1.45–7.33) 0.004 
at least 3 events (n  = 31) 35.61 (5.99–65.22) 0.018   5.65 (1.51–21.19) 0.010 
Work     
at least 1 event (n= 421) 3.89 (-3.97–11.76)  0.332 1.54 (0.91–2.60)  0.106 
at least 2 events (n= 97) b 12.15 (-3.01–27.30) 0.116 2.78 (1.20–6.48) 0.018 
Social      
relationships     
at least 1 event (n= 425) 2.21 (-5.71–10.13) 0.584 1.41 (0.87–2.27) 0.162 
at least 2 events (n= 98) c 17.04 (1.48–32.60) 0.032  2.47 (1.09–5.60) 0.031 
Health     
at least 1 event (n= 592) 4.91 (-1.92–11.73) 0.159 1.56 (1.07–2.28) 0.022 
at least 2 events (n= 155) 15.37 (2.87–27.88) 0.016 a 1.81 (0.99–3.30) 0.054 
at least 3 events (n= 33) 32.13 (6.39–57.87) 0.014  1.07 (0.30–3.83) 0.923 
Housing     
at least 1 event (n= 86) d 27.25 (10.39–44.11) 0.002  4.06 (1.88–8.74) 0.001 
Across all life     
domains     
at least 1 event (n= 1111) 3.17 (-2.28–8.62) 0.254 1.43 (1.03–1.98) 0.033 
at least 2 events (n= 583) 6.06 (-0.88–12.99) 0.087 1.72 (1.15–2.57) 0.008 
at least 3 events (n= 300) 13.72 (4.55–22.88) 0.003  1.94 (1.17–3.22) 0.010 
at least 4 events (n= 174) 21.79 (10.09–33.48) 0.001 2.70 (1.51–4.85) 0.001 
at least 5 events (n= 88) 25.85 (9.82–41.87) 0.002 2.66 (1.18–6.00) 0.018 
at least 6 events (n= 45) e 36.09 (13.29–58.88) 0.002 2.77 (0.88–8.68) 0.081 
Note. No stressful life events refer to a category combining individuals who report no stressful 
life events or life events that are not at all or mildly stressful; Extremely stressful life events 
refer to a category combining individuals who report moderately or extremely stressful life 
events; Number of individuals in parenthesis refers to the number in the extremely stressful life 
events category; Associations between stressful life events and IGT (no vs. yes (n = 219)) were 
tested using logistic regression analyses and therefore odds ratios are presented; All the other 
associations were tested using linear regression analyses. The scale of HOMAIR was skewed. 
Therefore, they were log-transformed for the analyses and their units are presented as percents;  
a Association is no longer significant when further adjusting for depressive symptoms; b Number 
of participants reporting at least 3 events was 9, therefore this category is not analysed 
separately; c Number of participants reporting at least 3 events was 14, therefore this category is 
not analysed separately; d Number of  participants  reporting at  least  2  events  was 20,  therefore 
this category is not analysed separately; e Number of participants reporting at least 7 events was 
25, therefore this category is not analysed separately.  
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4.3.2 Are stressful life events associated with IR and insulin secretion in 
individuals without T2D? 
 
Additional analysis showed that when further excluding participants with previously 
known diabetes or those with diagnosis based on OGTT (n = 182), stressful life events 
related to accumulation of finance-, health- and home-related domains, and the 
accumulation  of  at  least  3  events  were  associated  with  IR  (Table  11).  In  addition,  no  
associations were found with insulin secretion (Table 11). Finally, except for 
accumulation of at least one financial stress-related event, these associations remained 
statistically significant when models were further adjusted for depressive symptoms 
measured with SF-36.  
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Table 11. Fully adjusted (sex, age, alcohol consumption, current smoking status, regular 
exercise, level of education and family history of diabetes) associations between accumulation 
of stressful life events during the past 12 months with IR. Participants with T2D excluded         
(n = 182). 
No (n = 2166) versus HOMAIR  CIR  
accumulation of extremely % change  % change  
stressful life events: (95% CI) p (95% CI) p 
Finance     
at least 1 event (n = 258) 9.1 (0.1–18.0) 0.047 a -1.8 (-13.1–9.5) 0.751 
at least 2 events (n = 92) 18.9 (4.4–33.3) 0.011  -6.8 (-25.3–11.7) 0.472 
at least 3 events (n = 30) 36.9 (10.2–63.7) 0.007  -9.1 (-43.2–25.0) 0.602 
Work      
at least 1 event (n = 406) 5.8 (-1.4–12.9) 0.114 -0.3 (-9.4–8.7) 0.940 
at least 2 events (n = 91) b 12.5 (-1.6–26.5) 0.082 11.1 (-6.8–29.1) 0.222 
Social relationships     
at least 1 event (n = 403) 2.4 (-5.0–9.7) 0.530 -1.9 (-11.0–7.2) 0.681 
at least 2 events (n = 91) c 9.7 (-4.9–24.2) 0.193 -11.8 (-30.3–6.7) 0.210 
Health      
at least 1 event (n = 562) 4.1 (-2.2–10.5) 0.202 -4.6 (-12.6–3.3) 0.254 
at least 2 events (n = 140) 12.3 (0.4–24.1) 0.042  -0.3 (-15.1–14.6) 0.973 
at least 3 events (n = 27) 24.9 (-0.6–50.3) 0.055 1.2 (-30.6–33.1) 0.939 
Housing      
at least 1 event (n = 83) d 24.5 (9.1–40.0) 0.002  6.0 (-13.7–25.8) 0.550 
Across all life domains     
at least 1 event (n =1059) 3.1 (-1.9–8.1) 0.224 -2.1 (-8.4–4.2) 0.515 
at least 2 events (n = 554) 4.3 (-2.1–10.8) 0.189 -1.0 (-9.1–7.2) 0.818 
at least 3 events (n = 283) 12.9 (4.3–21.4) 0.003  -0.2 (-11.0–10.6) 0.973 
at least 4 events (n = 164) 22.3 (11.5–33.2) 0.001 1.2 (-12.5–14.9) 0.864 
at least 5 events (n = 82) 24.6 (9.6–39.6) 0.001 -2.1 (-21.1–16.9) 0.828 
at least 6 events (n = 41) e 32.0 (10.6–53.5) 0.003 -4.1 (-31.8–23.6) 0.772 
Note. No stressful life events refer to a category combining individuals who report no stressful 
life events or life events that are not at all or mildly stressful; Extremely stressful life events 
refer to a category combining individuals who report moderately or extremely stressful life 
events; Number of individuals in parenthesis refer to number reporting extremely stressful life 
events; a Association is no longer significant when further adjusting for depressive symptoms;   
b Number of participants reporting at least 3 events was 9, therefore this category is not analysed 
separately; c Number of participants reporting at least 3 events was 13, therefore this category is 
not analysed separately; d Number of  participants  reporting at  least  2  events  was 15,  therefore 
this category is not analysed separately; e Number of participants reporting at least 7 events was 
22, therefore this category is not analysed separately.  
 
 
 
74 
 
4.4 Studies III & IV: Are depressive symptoms and stressful life 
events associated with the MetS?  
 
4.4.1 Study III: Are depressive symptoms and antidepressant medication 
associated with the MetS? 
 
Depressive symptoms were associated with use of antidepressant medication: per each 
one standard deviation (SD) unit increase in depressive symptoms, the odds for 
antidepressant medication use increased by 2.62-fold (95% CI, 2.24, 3.07, p=0.001; for 
men OR = 2.89, 95% CI, 2.11, 3.96, p=0.001; for women OR = 2.53, 95% CI, 2.11, 
3.04, p=0.001).  
Further, depressive symptoms were significantly associated with increased odds for 
having the MetS (Table 12). Depressive symptoms remained a significant predictor of 
MetS in all models except for one: when participants with established diabetes and 
CVD were excluded and mediating and confounding factors were controlled, the 
association was rendered non-significant (Table 12). Antidepressant medication use was 
also significantly associated with increased odds for having the MetS (Table 12). 
However, after exclusion of participants with established diabetes and CVD and 
controlling for mediating and confounding factors the association was no longer 
significant. 
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Table 12. Prevalence of the MetS according to presence of depressive symptoms and use of 
antidepressant medication. 
 Total sample  Subjects without 
diabetes or CVD a 
 
 n Odds Ratio p n Odds Ratio p 
Depression:  (95% CI)   (95% CI)  
Depressive symptoms        
(SD units)       
  Sex and age  4967 1.11 (1.04–1.19) 0.002 4428 1.10 (1.02–1.18) 0.013 
  adjusted model       
  Fully adjusted model 4967 1.10 (1.03–1.18) 0.006 4428 1.07 (1.00–1.16) 0.067 
Participants with        
antidepressant        
medication       
use excluded a, b 4793 1.10 (1.03–1.17) 0.006 4280 1.09 (1.01–1.17) 0.026 
Depressive symptoms        
(top quartile vs. lower       
three quartiles)       
  Sex and age  4967 1.28 (1.11–1.49) 0.001 4428 1.24 (1.05–1.46) 0.010 
  adjusted model       
  Fully adjusted model 4,967 1.26 (1.07–1.47) 0.004 4428 1.19 (1.00–1.41) 0.053 
Participants with        
antidepressant        
medication       
use excluded a, b 4793 1.28 (1.10–1.49) 0.002 4280 1.24 (1.05–1.47) 0.011 
Antidepressant        
medication       
use (no vs. yes)       
  Sex and age  4967 1.51 (1.08–2.10) 0.015 4428 1.51 (1.05–2.18) 0.027 
  adjusted model       
  Fully adjusted model 4967 1.52 (1.07–2.15) 0.019 4428 1.46 (0.99–2.14) 0.054 
Note. MetS was defined using the harmonized clinical criteria. Fully adjusted refers to a model 
adjusting for sex, age, physical activity, alcohol consumption, current smoking status, 
occupational status and family history for diabetes. a Number of participants excluded was 539. 
b Model was adjusted for sex and age  
 
In addition, the associations between depressive symptoms, antidepressant 
medication use and individual components of MetS as continuous variables were 
analysed (data not shown). The results indicated that depressive symptoms were 
significantly associated with higher 2-h glucose, higher triglycerides and lower HDL-
cholesterol, and higher waist circumference. These associations remained significant in 
models adjusting for mediating and confounding factors, and when excluding those 
participants who reported antidepressant medication use. Depressive symptoms were 
not associated with fasting glucose or SBP or DBP. However, depressive symptoms 
were associated with higher fasting glucose when participants with CVD or diabetes 
were included in the analysis. When individuals with depressive symptoms scores in the 
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top and the lower three quartiles were contrasted the results remained virtually identical. 
Use of antidepressant medication was significantly associated with higher triglycerides, 
waist circumference and SBP, but it was unrelated to fasting and 2-h glucose and HDL-
cholesterol and DBP. 
 
4.4.2 Study IV: Are stressful life events associated with the MetS?  
 
First, the association of single stressful life events with MetS (Table 13), and thereafter 
the accumulation of stressful life events with MetS (Table 14) are presented. 
The results of Study IV showed that the odds for having the MetS according to the 
ATP III, the IDF or both criteria was significantly higher among participants who had 
experienced extremely stressful life events in finance-, (ongoing financial strain, severe 
financial strain, threat of unemployment or personal bankruptcy), work-, (troubles with 
co–workers, beginning a new job) or health-related domains (concern over own or 
child’s ability to cope with stress) (Table 13). Finally, associations of ongoing financial 
strain and beginning a new job with ATP III definition for MetS were not significant 
when participants with diabetes (n = 182) were excluded from the analysis and/or when 
models were further adjusted for depressive symptoms measured with SF-36.  
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Table 13. Fully adjusted (sex, age, alcohol consumption, current smoking status, regular 
exercise, level of education and family history of diabetes) associations between stressful life 
events during the past 12 months with the MetS according to the ATP III and the IDF criteria. 
 ATP III  IDF  
No (n = 2296) versus extremely Odds ratio  Odds ratio  
stressful life events:  (95% CI) p (95% CI) p 
Finance     
1. Ongoing financial strain (n = 213) 1.60 (1.07–2.39) 0.023 a 1.24 (0.85–1.81) 0.267 
2. Severe financial strain,  laid off 2.80 (1.69–4.63) 0.001 2.10 (1.29–3.42) 0.003 
business (n = 100)     
3. Threat of unemployment or 2.90 (1.70–4.94) 0.001 1.95 (1.16–3.27) 0.012 
personal bankruptcy (n = 89)     
Work     
4. Continuous work overload (n = 318) 1.17 (0.83–1.65) 0.381 1.15 (0.85–1.56) 0.361 
5. Troubles with co–workers (n = 167) 1.79 (1.17–2.75) 0.007 1.75 (1.18–2.59) 0.005 
6. Began a new job (n = 42) 2.29 (1.05–4.98) 0.037 a 1.93 (0.92–4.02) 0.081 
Social relationships     
7. Ongoing difficulties in close 0.95 (0.56–1.62) 0.856 0.86 (0.54–1.37) 0.521 
relationships (n = 160)     
8. Divorced or separated from 1.44 (0.90–2.31) 0.127 1.31 (0.85–2.01) 0.220 
husband/wife/partner (n = 153)     
9. Death of spouse/partner/close 1.17 (0.79–1.72) 0.431 1.07 (0.75–1.53) 0.692 
friend (n = 224)     
Health     
10. Serious injury or illness (n = 194) 1.29 (0.87–1.91) 0.210 1.15 (0.80–1.66) 0.454 
11. Concern over health of a family 1.20 (0.88–1.62) 0.246 1.07 (0.81–1.42) 0.609 
member or a close friend (n = 376)     
12. Concern over own or child’s 1.59 (1.11–2.28) 0.012 1.26 (0.89–1.79) 0.186 
ability to cope with stress (n = 210)     
Housing     
13. Loss of home (n = 26) 1.67 (0.61–4.55) 0.314 1.84 (0.68–4.97) 0.232 
14. Change of residence (n = 58) 1.22 (0.53–2.82) 0.643 1.13 (0.53–2.42) 0.758 
15. Difficulties in housing (n = 22) 2.51 (0.89–7.05) 0.081 b 1.80 (0.65–5.03) 0.261 
Note. No stressful life events refer to a category combining individuals who report no stressful 
life events or life events that are not at all or mildly stressful; Extremely stressful life events 
refer to a category combining individuals who report moderately or extremely stressful life 
events; Number of individuals in parenthesis refer to the number reporting extremely stressful 
life events. a Association is no longer significant when further adjusting for depressive 
symptoms and/or when excluding participants with diabetes;  b Association becomes statistically 
significant when participants with diabetes are excluded. 
 
Further, the odds for having the MetS according to the ATP III and the IDF criteria 
was significantly higher among participants who had experienced at least one stressful 
life event in the finance-related domain, and at least three events in any of the life 
domains (Table 14). Furthermore, all associations remained significant when 
participants with diabetes were excluded from the analysis, except for one: association 
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of accumulation of at least two health-related stressful life events with ATP III for the 
MetS was no longer significant. Finally, the associations in participants without diabetes 
remained statistically significant when further adjusting for depressive symptoms 
measured with SF-36. 
 
Table 14. Fully adjusted (sex, age, alcohol consumption, current smoking status, regular 
exercise, level of education and family history of diabetes) associations between accumulation 
of  stressful  life  events  during the past  12 months with MetS according to the ATP III  and the 
IDF criteria. 
 ATP III  IDF  
No (n = 2296) versus     
accumulation of extremely Odds ratio  Odds ratio  
stressful life events: (95% CI) p (95% CI) p 
Finance     
at least 1 event (n = 273) 1.78 (1.25–2.53) 0.001 1.42 (1.03–1.98) 0.036 
at least 2 events (n = 98) 2.91 (1.75–4.89) 0.001 1.85 (1.12–3.05) 0.016 
at least 3 events (n = 31) 4.08 (1.66–10.06) 0.002 2.82 (1.15–6.92) 0.023 
Work      
at least 1 event (n = 421) 1.34 (0.99–1.81) 0.061 1.30 (0.99–1.70) 0.058 
at least 2 events (n = 97) a 1.70 (0.99–2.92) 0.055 1.63 (0.99–2.66) 0.053 
Social relationships     
at least 1 event (n = 425) 1.13 (0.83–1.53) 0.447 1.06 (0.81–1.40) 0.666 
at least 2 events (n = 98) b 1.56 (0.88–2.75) 0.125 1.25 (0.73–2.14) 0.419 
Health      
at least 1 event (n = 592) 1.23 (0.96–1.59) 0.101 1.12 (0.89–1.41) 0.347 
at least 2 events (n = 155) 1.65 (1.10–2.50) 0.016 c 1.27 (0.85–1.88) 0.240 
at least 3 events (n = 33) 1.45 (0.63–3.34) 0.378 1.06 (0.47–2.40) 0.888 
Housing      
at least 1 event (n = 86) d 1.56 (0.84–2.91) 0.163 1.36 (0.76–2.45) 0.304 
Across all life domains     
at least 1 event (n =1111) 1.21 (0.98–1.49) 0.075 1.09 (0.90–1.31) 0.395 
at least 2 events (n = 583) 1.42 (1.10–1.84) 0.008 1.16 (0.91–1.47) 0.225 
at least 3 events (n = 300) 1.64 (1.18–2.28) 0.003 1.47 (1.08–1.99) 0.013 
at least 4 events (n = 174) 1.91 (1.28–2.86) 0.002 1.81 (1.24–2.64) 0.002 
at least 5 events (n = 88) 2.23 (1.31–3.81) 0.003 1.78 (1.06–2.98) 0.028 
at least 6 events (n = 45) e 2.95 (1.43–6.11) 0.004 2.70 (1.32–5.52) 0.007 
Note. No stressful life events refer to a category combining individuals who report no stressful 
life events or life events that are not at all or mildly stressful; Extremely stressful life events 
refer to a category combining individuals who report moderately or extremely stressful life 
events; Number of individuals in parenthesis refer to number reporting extremely stressful life 
events; a Number of participants reporting at least 3 events was 9, therefore this category is not 
analysed separately; b Number of participants reporting at least 3 events was 14, therefore this 
category is not analysed separately; c Association is not statistically significant when 
participants with diabetes are excluded from the analysis; d Number of participants reporting at 
least 2 events was 20, therefore this category is not analysed separately; e Number of 
participants reporting at least 7 events was 25, therefore this category is not analysed separately. 
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5 DISCUSSION 
 
This thesis aimed to assess the associations of depressive symptoms, poor sleep quality 
and stress with IR and the MetS in participants free of T2D. Depressive symptoms, 
subjective  sleep  complaints  and  stressful  life  events  were  associated  with  IR,  but  not  
with insulin secretion (Studies I, II & IV). Furthermore, depressive symptoms and 
stressful life events were associated with increased odds for MetS (Studies III & IV). In 
addition, association between depressive symptoms, MetS and IR was not driven by use 
of antidepressant medication (Studies I & III), nor by CVD (Study III). Finally, 
presented in this summary of findings, additional analyses showed that the association 
of stressful life events with IR and the MetS remained in participants free of T2D and 
when further adjusting for depressive symptoms. These results implicate that 
psychosocial factors may, as hypothesized, pose a risk to metabolic dysfunctions and 
may further add to development of T2D. However the direction of causality needs to be 
confirmed in a longitudinal setting. The findings will be discussed in more detail next, 
followed by study limitations, strengths and conclusions with future directions. 
 
5.1 The association of depressive symptoms with IR and the 
MetS 
 
Results of Study I showed that per one SD unit increase in depressive symptoms odds 
for being insulin resistant increased approximately 9-20%, but depressive symptoms 
were not associated with changes in insulin response when corrected for IR (CIR). In 
addition, significant interactions between depressive symptoms and antidepressant 
medication were not found regarding associations of depressive symptoms to IR. The 
findings, thus, suggest that depressive symptoms are associated with IR, even in 
individuals without diabetes, and that use of antidepressant medication may not explain 
these effects. Previous studies have produced a contradictory pattern of findings with 
some reporting a positive (Adriaanse et al., 2006; Everson-Rose et al., 2004; Holt et al., 
2009; Pan et al., 2008; Pearson et al., 2010; Timonen et al., 2006; Timonen et al., 2007) 
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and some no association between depressive symptoms and IR (Golden et al., 2007; 
Lawlor et al., 2005; Qiuhua et al., 2011; Roos et al., 2007), and some that depressive 
symptoms may improve insulin sensitivity (Lawlor et al., 2003). In addition, results are 
also  in  accord  with  a  study  that  found  no  association  to  insulin  secretion  (Holt  et  al.,  
2009). These findings add to the literature by suggesting that use of antidepressant 
medication is not the reason why previous studies have produced such a mixed pattern. 
The findings also suggest that while use of antidepressant medication was associated 
with higher odds for belonging to the top quartile in HOMAIR, the somewhat different 
pattern of associations found for depressive symptoms and for use of antidepressant 
medication may suggest that different underlying mechanisms explain these 
associations. While this study was cross-sectional, which is an obvious and major 
limitation, the fact that the associations depicted participants with no known diabetes, 
suggests that depressive symptoms may play a role earlier in the process that later on 
manifests in T2D and related disorders. Indeed, a consistent finding of a positive 
association between depression as a potential explanatory factor and IR as the main 
outcome would suggest that the depression–diabetes link may simply represent a 
snapshot in time of the effects of depression on glucose metabolism reflecting that these 
potential effects of depression may begin much earlier in the life span of the individual. 
Study III examined associations between depressive symptoms and antidepressant 
medication use with MetS and it’s individual components. These findings showed that 
per each SD unit increase in depressive symptoms the odds for having the MetS 
increased over 10%. Antidepressant medication users had a 50% increased odds for 
having the MetS.  These findings are, thus, in agreement with the majority of previously 
published studies showing an association between depression and MetS (Akbaraly et al., 
2009; Akbaraly et al., 2011; Kinder et al., 2004; Pulkki-Råback et al., 2009; Räikkönen 
et al., 2007; Toker et al., 2008; Vaccarino et al., 2008; Valtonen et al., 2008; Vanhala et 
al., 2009; Vogelzangs et al., 2007). These findings, however, add significantly to the 
existing literature by showing that even though depressive symptoms and antidepressant 
medication use were in this study, and as reported by others, strongly related (Everson-
Rose et al., 2004; Rubin et al., 2008; Vaccarino et al., 2008; Vogelzangs et al., 2007), 
the association between depressive symptoms and the MetS was not secondary to the 
use of antidepressant medication.  
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With regard to findings pertaining to the individual components of the MetS, 
depressive symptoms were associated with higher 2-hour glucose levels, higher 
triglycerides and lower HDL-cholesterol levels and higher waist circumference, but they 
were not associated with fasting glucose or BP values. Again the association between 
depressive symptoms and glucose, lipids and waist circumference was not secondary to 
antidepressant medication use. Antidepressant medication use, in turn, was associated 
with higher triglycerides, waist circumference and SBP, but not with fasting or 2-hour 
glucose levels, HDL-cholesterol and DBP.  
The concept and the definition of the MetS have recently been criticized (R. Kahn et 
al., 2005; Simmons et al., 2010). The cut-off values of the components used in the 
definition of the MetS are arbitrary as many of the risk factors are linearly associated 
with CVD (R. Kahn et al., 2005; Simmons et al., 2010). These findings, thus, suggest 
that the association between depression and the MetS is not driven by the somewhat 
arbitrary cut-off levels used in the definition of the MetS. Rather, depression and 
components of MetS seem to associate with each other in a dose-response manner. The 
somewhat different pattern of associations found for depressive symptoms and 
antidepressant medication may suggest that depressive symptoms and antidepressant 
medication use may contribute to MetS and associated disorders via somewhat different 
mechanisms. This is not surprising given that not all individuals scoring high on 
depressive symptoms are currently using antidepressant medication, and not all 
antidepressant medication users score high on depressive symptoms. In other words, the 
self-rated depressive symptoms screen, but do not diagnose individuals with clinical 
depression.  
Further, it has been claimed that the MetS is not a syndrome, but a premorbid state, 
and therefore individuals with established diabetes and CVD should be excluded from 
the definition (R. Kahn et al., 2005; R. Kahn, 2006; Simmons et al., 2010). Roughly 
10% of the sample were excluded with established diabetes or CVD from the analyses 
and it was found that even when individuals with these disorders were excluded, 
depressive symptoms and antidepressant medication use remained significantly 
associated with MetS and with higher levels of it’s individual components. These 
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findings thus suggest that the previously established link between depression and MetS 
is not driven by having diabetes or CVD.  
 
5.2 The association of subjective sleep complaints with IR 
 
Study II tested the associations between subjective sleep complaints and their co-
occurrence with IR and insulin secretion in individuals without a history of or 
concurrently  diagnosed  T2D.  Findings  showed  that  in  comparison  to  individuals  with  
none/minor sleep complaints those with more frequent complaints of sleep apnea, 
insomnia and daytime sleepiness were significantly more insulin resistant. Further, 
results showed that the likelihood of being insulin resistant increased significantly and 
linearly according to co-occurring sleep-complaints. These associations changed only a 
little when adjustments were made for sex, age, BMI, lifestyle, occupation and family 
history for diabetes. The associations did not change when adjustments were made for 
depressive symptoms. Complaints of sleep apnea associated with deficiency in insulin 
secretion (DI), but this association was rendered non-significant when adjusted for the 
mediating and confounding factors. The findings thus suggest that IR rather than 
deficiency in insulin secretion is characteristic of individuals reporting more frequent 
sleep complaints. 
These findings agree with the previous research suggesting that those who suffer 
from sleep disordered breathing by displaying a more severe apnea-hypopnea index in 
polysomnography were more likely to be insulin resistant (Punjabi et al., 2002; Punjabi 
& Beamer, 2009; Seicean et al., 2008). Findings of Study II, however, disagree with a 
report (Punjabi & Beamer, 2009) showing that sleep apnea was associated with 
impairments in pancreatic ?-cell function (DI) (Punjabi & Beamer, 2009). In Study II 
sleep  apnea  and  DI  were  associated  in  an  unadjusted  model,  but  when  we  made  
adjustments for the mediating and confounding factors this association was rendered 
non-significant. The findings also disagree with the null associations found between 
subjective complaints of sleep apnea/snoring and IR (Knutson et al., 2011; Renko et al., 
2005). However, findings of Study II do not either confirm the null associations of 
complaints of daytime sleepiness with IR (Renko et al., 2005), or the association of 
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actigraphy- and complaint-based measure of insomnia with lower likelihood of being 
insulin resistant (Knutson et al., 2011). 
The discrepant findings may rise from methodological differences. Participants of the 
PPP-Botnia Study underwent an OGTT providing us the opportunity to exclude 
individuals with newly diagnosed T2D based on fasting and 2-hr values for T2D. 
Except for studies by (Seicean et al., 2008) and (Renko et al., 2005), individuals with 
new T2D have, in the previous studies, been excluded based on fasting values for T2D 
only (Knutson et al., 2011; Punjabi et al., 2004), even if an OGTT (Punjabi et al., 2002) 
or an IVGTT (Punjabi & Beamer, 2009) have identified additional responses 
characteristic of T2D. It should also be kept in mind that we measured subjective sleep 
complaints, though with a validated questionnaire (Partinen & Gislason, 1995), which 
as a methodology is different from polysomnography and actigraphy. Yet, 
epidemiological evidence points to an increased risk of T2D also for individuals with 
subjective sleep complaints (Cappuccio et al., 2010; Knutson et al., 2011; Meisinger et 
al., 2005; Nilsson et al., 2004; Seicean et al., 2008; Spiegel et al., 2005). Finally, a 
majority of the existing studies has focused on sleep disordered breathing, and in only 
two of the studies more than one sleep disorder/complaint has been measured. Even 
though sleep disorders and complaints co-occur (Barcelo et al., 2008; D. E. Ford & 
Kamerow, 1989; Ohayon et al., 1998; Ohayon & Partinen, 2002), no previous study has 
tested if the likelihood of being insulin resistant increases according to co-occurring 
sleep complaints. 
 
5.3 The association of stressful life events with IR and the MetS 
 
The key finding according to Study IV is that individuals who reported extremely 
stressful life events within finance- and work-related life domains was associated with 
higher IR, measured with HOMAIR, and had significantly higher odds for having MetS. 
The  risk  for  MetS  was  further  increased  up  to  four  fold  according  to  accumulation  of  
stressful finance-related events and up to three fold according to having at least three 
events in any of the life domains measured, namely finance, work, social relationships, 
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health and housing. Accumulation of stressful finance-, and work-related life events and 
having at least three stressful events in any of the life domains associated significantly 
also  with  obesity  and  triglycerides.  In  addition,  all  domains  and  accumulation  across  
domains were associated with increased odds for IGT. The associations were not 
confounded by sex, age, lifestyle or family history of diabetes. Finally, in this summary 
I presented a further finding that the association of stressful life events with IR remained 
after excluding participants with diabetes and when further adjusting for depressive 
symptoms. In conclusion, the association of stressful life events with IR were not driven 
by manifest or latent T2D and were associated with IR independent of depressive 
symptoms. 
The findings in Study IV are in agreement with previous studies (Chandola et al., 
2006; Horri et al., 2010; Räikkönen et al., 2007; Troxel et al., 2005; Vitaliano et al., 
2002; Vogelzangs et al., 2007; Zhang et al., 2006) by showing that major stress-related 
events associate with an increased risk for having the MetS and IR. However, these 
findings further suggest that out of the life events measured, those relating more 
specifically to finance and work seemed the most harmful. While chronic work stress 
has been associated with an increased risk for having MetS in the Whitehall II study 
(Chandola et al., 2006), the other existing studies have not specifically focused on work-
related stress and none of the studies on finance-related stress, precluding direct 
comparisons between the studies. One previous study showed that accumulation of non-
work-related stressful life events were associated with increased risk of obesity in men, 
higher waist-hip-ratio in women and men, but not with fasting insulin concentrations 
(Mooy et al., 2000), findings that are at least partially in line with the current ones. 
Another study (Horri et al., 2010) showed that the prevalence of MetS increased in a 
similar dose-response manner according to accumulation of stressful life events 
indicating that accumulation of events add to odds for MetS beyond single events. 
Additional analysis presented in this summary showed that stressful life events are also 
associated with IR in individuals without diabetes that is also in line with the study by 
(Zhang et al., 2006). In conclusion, results of Study IV are in line with Björntorp’s 
theory, as stressful life events were found to relate to indices of obesity and IR.  
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5.4 Possible mechanisms linking psychosocial factors with IR 
and the MetS 
 
Findings  presented  in  this  thesis,  particularly  with  the  different  components  of  the  
MetS, agree well with the work and hypothesis put forward by Björntrop (Björntorp, 
1991; Björntorp et al., 1999). However, due to the cross-sectional design of the study, 
the pathophysiological mechanisms underlying the associations cannot be addressed. 
Findings presented in this thesis may, however, mirror alterations in the physiological 
stress-regulatory mechanisms. Altered activity of the HPAA is among the most 
consistently demonstrated biological abnormalities in depression (E. S. Brown, 
Varghese, & McEwen, 2004), poor sleep (Pesonen et al., 2012; Räikkönen et al., 2010) 
and in severe stress (Chrousos & Gold, 1992; Hjemdahl, 2002). HPAA hyperactivity 
due to exposure to extreme stress or due to depressive symptoms followed by increased 
release of counterregulatory hormones and cortisol, increases IR and decreases glucose 
transport function (E. S. Brown et al., 2004; Musselman et al., 2003; Ramasubbu, 
2002). Higher levels of cortisol have also shown to be related to the development of the 
MetS (Brunner et al., 2002; Licht et al., 2010) and to sleep disorders (Vgontzas et al., 
1999), and excess in glucocorticoids has been linked with lower mood in participants 
with T2D (Reynolds et al., 2012). According to findings presented in this thesis, it may 
be that perceived or anticipated environmental stressors, even of mild or moderate 
severity,  exert  profound influences,  and  the  severity  and  quality  of  such  stressors  are,  
according to Björntorp, followed by a `dose-response' of cortisol secretion (Björntorp et 
al., 1999).  
Furthermore, Björntorp postulated that dysregulation of the HPAA promotes 
deposition of visceral adipose tissue (Björntorp, 1991; Björntorp & Rosmond, 2000). 
Adipose tissue secretes a large number of hormones and cytokines, such as interleukin 
(IL)-1 and IL-6 and TNF-? (Hotamisligil et al, 1993; Yudkin et al., 2000), and these 
cytokines are considered to be a key factor in the metabolic abnormalities of IR and the 
MetS (Hajer, van Haeften, & Visseren, 2008; G. M. Reaven, 1988; Taylor, 2008). In 
addition, there is convincing evidence showing that depression and stress are associated 
with increased release of immunoinflammatory cytokines (e.g. interleukin (IL)-1, IL-6, 
and  TNF-?)  that  contribute  to  development  of  IR  (Elenkov,  Iezzoni,  Daly,  Harris,  &  
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Chrousos, 2005; P. H. Black, 2006; Vgontzas et al., 2000; Vgontzas & Chrousos, 2002). 
Finally, there is also evidence showing that proinflammatory cytokines contribute 
toward  daytime  sleepiness  and  fatigue  and  are  believed  to  play  key  roles  in  sleep  
pathology, such as sleep apnea (Vgontzas & Chrousos, 2002).  
The positive association between depression and inflammation may also be the result 
of a complex, bidirectional process in which central nervous system correlates of 
depression alter immunity and vice versa (Kiecolt-Glaser & Glaser, 2002; Kop & 
Gottdiener, 2005; Penninx et al., 2003). For example, depression is associated with 
decreased parasympathetic activity in the ANS, which results in increased inflammation 
in the body (Kop & Gottdiener, 2005). In turn, these inflammatory processes directly 
influence the central nervous system via heightened HPAA activity because 
proinflammatory cytokines, such as IL-6, stimulate the release of CRH (Penninx et al., 
2003). Increased HPAA activity can lead to elevated cortisol levels which are known to 
initiate and/or worsen symptoms of depression (Kiecolt-Glaser & Glaser, 2002). Much 
evidence supports this reciprocal hypothesis (Capuron, Ravaud, Miller, & Dantzer, 
2004; Maier & Watkins, 1998).  
Yet another plausible biologic factor mediating the relationship between obesity and 
depressive symptoms is leptin. This hormone, which is produced in the adipose tissue, 
signals through different brain pathways to inhibit appetite (Lu, 2007), and has been 
associated with depression in men (Labad et al., 2012) and women (Esel et al., 2005; 
Yang et al., 2007). Furthermore, causative mechanisms relating sleep problems to 
adverse health outcomes include reciprocal changes in circulating levels of leptin and 
ghrelin (Spiegel, Tasali, Penev, & Van Cauter, 2004; Taheri, Lin, Austin, Young, & 
Mignot, 2004). These in turn would increase appetite and caloric intake, reduce energy 
expenditure (Knutson et al., 2007; Spiegel et al., 2009), and facilitate the development 
of obesity (Spiegel et al., 2009; Taheri et al., 2004) and impaired glycemic control 
(Spiegel et al., 2005). Furthermore, the mechanisms of poor sleep and IR may also 
relate to physical and psychological stresses that accompany complaints of sleep apnea, 
insomnia and daytime sleepiness, such as hypoxia, sleep fragmentation, non-restorative 
sleep, irritable mood and problems in cognitive performance resulting in sympathetic 
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arousal (Barcelo et al., 2008; Birketvedt et al., 1999; Esler et al., 2001; Keckeis et al., 
2010; Martikainen et al., 2011; Tasali, Leproult, Ehrmann, & Van Cauter, 2008).  
Yet another interesting further mechanism relates to prenatal programming and early 
life adversities. Evidence exists indicating that a suboptimal early life environment 
reflected in smaller body size at birth is linked with both depression (Räikkönen et al., 
2007) and IGT and T2D (Eriksson, Osmond, Kajantie, Forsen, & Barker, 2006), and 
low birth weight has been associated with higher IR (Hovi et al., 2007). Furthermore, 
one of the most striking developments in this field has been the discovery over the last 
few years that the increased activity of the HPAA and excess in glucocorticoids might 
reflect a susceptibility that can be programmed in utero and  through  early  life  events  
(Entringer et al., 2008; Pariente & Lightman, 2008; Reynolds, 2010; Reynolds, 2012). 
Findings suggest that the HPAA hyperactivity previously described in depression might 
not be the consequence of depression per se, but rather the manifestation of persistent 
neurobiological abnormalities that predispose to depression (Pariente & Lightman, 
2008). This could also explain why previous studies, that have not taken into account 
early life stressors, have been inconsistent in documenting the presence of HPAA 
hyperactivity in depression (Pariente & Lightman, 2008). 
Furthermore, mechanisms related to lifestyle may also be involved. While findings 
presented in this thesis were not, in general, affected by controlling for smoking, alcohol 
consumption, physical activity, family history for diabetes; or by level of education 
(Study IV) or occupational status (Studies I-III) in participants without CVD or 
diabetes; these lifestyle factors rendered the association of depressive symptoms and the 
MetS non-significant (Study III). Lifestyle factors may, thus, partially explain this 
association in healthier populations, though this was only true for MetS, not for it’s 
individual components. However, in the other studies presented in this thesis, the same 
attenuating effect of lifestyle factors was not observed.  
Finally, a common genetic basis for these findings may underlie. While only a 
handful of specific genes have been nominated, these promising findings may shed light 
to co-morbid associations of depressive symptoms, stress and sleep disorders. This basis 
may rise from genetic variants that participate in the regulation of the human sleep-
wake cycle and that are implicated in diabetes and in hyperglycaemia, such as the 
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MTNR1B (melatonin receptor 1B) on chromosome 11 (Bouatia-Naji et al., 2009; 
Lyssenko et al., 2009), and has thus been speculated to be a possible link between sleep 
disturbances and T2D (Mulder, Nagorny, Lyssenko, & Groop, 2009). In addition, the 
most studied gene-by-environment risk factor for mental illness is the increased risk for 
major  depression  reported  among  persons  carrying  the  short  variant  (s allele)  of  a  
functional polymorphism in the serotonin transporter (5-HTT, SLC6A4) gene promoter 
and who have been exposed to stressful life events (Caspi et al., 2003). Yet another 
similar finding regarding 5-HTTLPR showed, that it is moderating the association 
between stress and depression (Karg, Burmeister, Shedden, & Sen, 2011). As a further 
evidence,  it  has  been  found  that  childhood  abuse  and  adult  traumatic  events  may  act  
synergistically in interaction with the s allele of the serotonin transporter promoter 
variant 5-HTTLPR to increase the risk for depressive symptoms independently from the 
lifetime diagnosis of post traumatic stress syndrome (Grabe et al., 2012). Accordingly, 
one possible approach to explain the findings is to study the gene-by-environment 
interactions.  
 
5.5 Methodological considerations 
 
5.5.1 Limitations of the study 
 
These studies have some limitations. An obvious limitation relates to generalizability 
from the findings beyond Caucasians and thus findings may not apply to people with 
other ethnic backgrounds. The other obvious limitation relates to the cross-sectional 
study design, precluding causal inferences: while depressive symptoms may increase 
the odds for MetS (Kinder et al., 2004; Räikkönen et al., 2007; Toker et al., 2008; 
Vaccarino et al., 2008; Valtonen et al., 2008; Vanhala et al., 2009; Vogelzangs et al., 
2007), there are studies pointing at a reverse possibility (Akbaraly et al., 2009; Akbaraly 
et al., 2011; Koponen et al., 2008; Nouwen et al., 2010). The same rationale applies to 
other studies as well. Sleep complaints may be a consequence of dysfunctions in 
glucose metabolism after a recent longitudinal study found that higher insulin, but not 
glucose values, may increase the risk of sleep apnea (Balkau et al., 2010), and insomnia 
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and daytime sleepiness may result from hyperglycaemia. Furthermore, prospective 
studies in large population-based samples have demonstrated a bidirectional association 
between visceral obesity and depression because depressive symptoms result in 
increased abdominal obesity (Vogelzangs et al., 2008) and abdominal obesity is 
predictive of depressive symptoms (Akbaraly et al., 2009; Akbaraly et al., 2011; Pan et 
al., 2012). Indeed, due to cross-sectional study design, it cannot be ruled out that indeed 
the direction of causality is opposite. Nevertheless, it may be that the association 
between depressive symptoms and MetS and T2D, and depressive symptoms and IR, 
may be bi-directional (Golden et al., 2008; Pan et al., 2012; Räikkönen et al., 2002) and 
therefore treating one condition may prevent or treat the other, which is of considerable 
public health benefit. However, one of the main findings implicated by the results of 
this study is that the direction of causality regarding diagnosis per se or complications 
of  T2D  causing  stress  or  depression  was  ruled  out  as  participants  with  T2D  were  
excluded from the analysis.  
Regarding sleep complaints, it should also be kept in mind that although subjective 
sleep complaints were measured with a validated questionnaire (Partinen & Gislason, 
1995), it is as a methodology different from polysomnography. Yet, epidemiological 
evidence points to an increased risk for T2D also in individuals with subjective sleep 
complaints (Cappuccio et al., 2010; Knutson et al., 2011; Meisinger et al., 2005; Nilsson 
et al., 2004; Seicean et al., 2008; Spiegel et al., 2005). Further, different self-reported 
questionnaires have been used in different studies and therefore the findings are not 
directly comparable between different studies. The questions to capture sleep apnea, 
insomnia and/or daytime sleepiness in questionnaires, such as the BNSQ (Partinen & 
Gislason, 1995), the Pittsburgh Sleep Quality Index (Buysse, Reynolds, Monk, Berman, 
& Kupfer, 1989) and the Berlin Sleep Apnea Questionnaire (Netzer et al., 1999) are, 
however, similar, though the timeframe, and quantitative and qualitative measurement 
scales vary slightly. The questionnaires also vary in the degree in which input form a 
roommate/bed partner is requested in questions capturing sleep apnea.  Due to third 
party involvement, though, the validity of the scale is increased. However, in case no 
other  person  is  available  to  confirm  signs  of  sleep  apnea,  a  number  of  cases  remain  
undetected. This, however, diminished our ability to detect significant findings rather 
than increased. Finally, a majority of the existing studies has focused on sleep 
90 
 
disordered breathing, and in only two of the studies more than one sleep 
disorder/complaint has been measured. Even though sleep disorders and complaints co-
occur (Barcelo et al., 2008; Ohayon et al., 1998), no previous study has tested if the 
likelihood of being insulin resistant increases according to co-occurring sleep 
complaints.   
Finally, while in Studies I and III participants on antipsychotic medication and 
lithium were excluded from the analytic sample, data were not available on specific 
psychiatric disorders, and therefore it is not possible to address their role in explaining 
our findings in any further detail. The PPP-Botnia Study does not either include 
information on the length of antidepressant medication use, and therefore the question if 
medication used for a longer period in time is more detrimental than the use of the 
medication that started more recently, cannot be answered. Further, in Study IV 5.9% of 
our study population were excluded because of missing information, the major reason 
being missing data in life events questionnaire (5.3%). Those with full information, 
compared to those without, were younger, more educated, consumed more alcohol, had 
less frequently a family history of diabetes and met the criteria for MetS less frequently. 
In addition, 3.4% of population in Study I and 3.9% of population (3.7% without 
established diabetes and CVD) in Study III reported using antidepressant medication. 
The prevalence using antidepressant medication is somewhat lower than that reported in 
some other studies (Everson-Rose et al., 2004; Rubin et al., 2008; Vaccarino et al., 
2008). In addition, prevalence of MetS in Studies III and IV was lower (20-27% and 
30%, respectively) than the reported prevalence in Finland (Hu et al., 2008). This may 
partly be due to younger population of PPP-Botnia Study, however. Nevertheless, a bias 
towards inclusion of younger, more educated, and healthier participants, and the lesser 
sensitivity of the self-reported measure to capture antidepressant medication use, might 
diminish rather than increase the ability to detect significant associations.  
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5.5.2 Strengths of the study 
 
Strengths of this study lie in the population-based study design and detailed clinical 
examination. Also, data used in this thesis offered sufficient power to test sex-
specificity of the associations. While the association between depression and IR (Lawlor 
et al., 2003; Lawlor et al., 2005), depressive symptoms and MetS (Kinder et al., 2004; 
Toker et al., 2008; Vaccarino et al., 2008; Vanhala et al., 2009), and  stressful life 
events and the MetS (Vitaliano et al., 2002; Vogelzangs et al., 2007) have been reported 
to be different in men than in women, these data did not reveal such differences. In 
addition, while all associations were adjusted for level of education as a proxy of social 
position, a possibility remains that for a specific subgroup adjusting for level of 
education may not have been sufficient in capturing the overlap that may exist in social 
position and some of the stressful events (Study IV). Hence, in Studies I-III the level of 
education was replaced with occupational status to better grasp participants’ social 
position.  
Regarding the psychological measurements, stressful life events and their severity 
across various life domains contributed significantly to the existing literature. None of 
the prior studies testing associations between stress and the MetS have been population-
based or comprising data of both sexes, restricting the external validity of the findings. 
Occurrence and severity of stressful life events during the past 12 months were 
measured. Yet, it is not possible to determine the precise timing and duration of the life 
events, and hence it is not possible to address the temporal relationships between stress 
and  health  in  any  further  detail.  None  of  the  prior  studies  of  stress  and  MetS  has  
measured insulin and glucose after an oral glucose challenge precluding more precise 
definitions of the MetS and focus on glucose tolerance. Except for one (Räikkönen et 
al., 2007), none of the studies has measured the perceived severity of the stressful life 
events. Different events may pose different experiences in different individuals, thus 
separating out the perceived severity of different events (not equating events per se, 
such as death of a spouse, death of a pet) is important.  
Furthermore, the three psychosocial factors assessed in this thesis may overlap by 
definition,  exist  co-morbid  and  cause  the  onset  of  the  other.  For  example,  stress  has  
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been found to cause insomnia (Healey et al, 1981) and to trigger major depression 
(Kendler et al., 1995). Further, depression may decrease sleep quality (LeBlanc et al., 
2009; M.M. Ohayon, 2008b) and be a cause of insomnia (Morphy et al., 2007). 
However, as depressive symptoms were controlled for in studies regarding sleep 
complaints  and  stressful  life  events  (Studies  II  &  IV),  some  of  this  overlap  was  
dimished. It thus seems that association of poor sleep and stressful life events with IR 
may be independent of depressive symptoms. 
 
5.6 Conclusions, implications of the study and future directions 
 
The studies presented in this thesis provide implications for further research and for 
promoting public health (please see Table 15). 
In particular, the findings in this thesis inform of the premorbid mechanisms of 
cardio-metabolic diseases and this is an essential finding as T2D and its metabolic 
consequences pose a threat to individuals and a financial burden to society. As 
participants with T2D were excluded from the study samples, it seems that psychosocial 
factors play a role in the development of T2D by inducing IR – a process that may even 
date back some 10 years (U.K. Prospective Diabetes Study Group, 1995). However, as 
the causative cascade of events can not be addressed with these studies, future 
prospective studies are needed to define how these possibly overlapping psychosocial 
factors contribute to development of IR. Indeed, the causal evidence for an association 
between psychosocial factors and prediabetes is yet to be established, unlike the well-
established link between depression and manifest T2D. Nevertheless, the findings in 
this thesis suggest that interventions targeted at reducing depressive symptoms already 
at  subclinical  level,  and  the  consequences  of  stress  by  more  efficient  coping  skills,  as  
well as the causes of sleep complaints, may be beneficial in long-term health promotion. 
However, if indeed sub-clinical depressive symptoms and stressful life events are found 
an underlying cause of IR in a longitudinal setting, further studies could also include 
assessing the effectiveness of interventions in reducing the incidence of T2D. For 
example, a randomised controlled study could test whether effective prevention or 
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treatment of depression can reduce the incidence of T2D and its health consequences. 
Currently, there are few promising results implicating that psychological interventions, 
e.g. psychotherapy, might prove helpful in both alleviating the symptoms of depression 
and stress and improving glycemic control (Lustman, Griffith, Freedland, Kissel, & 
Clouse, 1998; Surwit et al., 2002). In addition to being based on a longitudinal setting, 
future studies addressing the interactions of specific genes and environment with IR are 
encouraged, as recent findings have implicated that depressive symptoms, poor sleep 
and stressful life events may share a common genetic background (Caspi & Moffitt, 
2006; Grabe et al., 2012; Karg & Sen, 2012; Kendler et al., 1995; Lyssenko et al., 2009; 
Mulder et al., 2009). Increasingly, it is becoming clear that few genetic and 
environmental factors act alone, but that instead they regularly act in concert to 
determine predisposition to psychiatric disorders (Carola & Gross, 2012; Caspi & 
Moffitt, 2006; Karg & Sen, 2012).  
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Table 15. Key findings, implications of the study and future directions. 
Key findings: 
? Subclinical depressive symptoms were associated with increasing odds for IR and the 
MetS 
? Subjective sleep complaints related to sleep apnea, insomnia and daytime sleepiness 
were associated with an increase in IR 
? Antidepressant medication failed to modify the associations of depressive symptoms 
with  IR  and  the  MetS,  but  it  was  also  found  to  contribute  to  IR  and  the  MetS  
independently  
? Stressful life events were associated with IR and the MetS  
? No associations were found between psychosocial factors and insulin secretion 
? The associations above were not driven by latent or established T2D 
? All findings above were not sex-specific 
 
Implications and future directions: 
? Controlling for and preventing already the subclinical psychosocial symptoms presented 
in this thesis may contribute beneficially to somatic health 
? Prospective studies are needed to confirm the direction of causality between 
psychosocial measures and IR.  
? People in a prediabetic condition are a key target group for psychosocial interventions, 
however, more research is needed to confirm the efficacy of these interventions on both 
psychological mood and glycemic control 
? Future studies need to address the gene-by-environment interactions as it is becoming 
increasingly clear that not only genetics nor solely environmental factors are the cause 
for psychiatric or somatic illness but they act in concert in contributing to disease onset 
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